ClinicalTrials.gg
CompletedNCT02365649Updated Dec 27, 2023Results posted

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

A Phase 2 interventional study of Placebo and ABT-494 in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
14th of 27
220 · median 220
Started
2015
with 3 others
Phase 2
8 of 55
2 open now
Registered
20th of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 20th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Crohn's disease (CD) for at least 90 days.
  2. Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450.
  3. Subject inadequately responded to or experienced intolerance to previous treatment with immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate) and/or anti-TNF agent (e.g., infliximab, adalimumab, or certolizumab pegol).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with ulcerative colitis (UC), collagenous colitis or indeterminate colitis.
  2. Subject who has had surgical bowel resections in the past 6 months or is planning resection.
  3. Subjects with an ostomy or ileoanal pouch.
  4. Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.
  5. Subject who has short bowel syndrome.
  6. Subject with recurring infections or active Tuberculosis (TB).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Active comparator
    Induction Period ABT-494 Twice Daily Medium/High Dose

    Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day

    Drug: ABT-494

  • Active comparator
    Extension Phase ABT-494 High Dose

    Extension Phase ABT-494 High Dose orally dosed twice a day

    Drug: ABT-494

  • Placebo comparator
    Induction Period Placebo

    Induction Period Placebo orally dosed twice a day

    Drug: Placebo

  • Active comparator
    Induction Period ABT-494 Low Dose

    Induction Period ABT-494 Low Dose orally dosed twice a day

    Drug: ABT-494

  • Active comparator
    Induction Period ABT-494 Once Daily Medium/High Dose

    Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day

    Drug: ABT-494

  • Active comparator
    Extension Phase ABT-494 Low Dose

    Extension Phase ABT-494 Low Dose orally dosed twice a day

    Drug: ABT-494

  • Active comparator
    Induction Period ABT-494 High Dose

    Induction Period ABT-494 High Dose orally dosed twice a day

    Drug: ABT-494

  • Active comparator
    Induction Period ABT-494 Low/Medium Dose

    Induction Period ABT-494 Low/Medium Dose orally dosed twice a day

    Drug: ABT-494

  • Active comparator
    Extension Phase ABT-494 Medium Dose

    Extension Phase ABT-494 Medium Dose orally dosed twice a day

    Drug: ABT-494

Interventions

  • DrugPlacebo

    Oral Dosing

  • Oral Dosing

    Also known as: Upadacitinib

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16

    Endoscopic remission was determined using Simplified Endoscopic Score for Crohn's Disease (SES-CD). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable.

    Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)

  2. Percentage of Participants Who Achieve Clinical Remission at Week 16

    Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 16

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

    Time frame: Week 16

  2. Percentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 16

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.

    Time frame: Week 16

  3. Percentage of Participants Who Achieve Clinical Remission at Week 12

    Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 12

  4. Percentage of Participants Who Achieve Remission at Week 16

    Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Week 16

  5. Percentage of Participants Who Achieve Response at Week 16

    Response is defined as endoscopic response at Week 12/16 AND clinical response at Week 16. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Week 16

  6. Percentage of Participants With Endoscopic Response at Week 12/16

    Endoscopic response: SES-CD at least 25% reduction from Baseline. Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Up to Week 16 (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)

  7. Percentage of Participants Who Achieve Clinical Response at Week 16

    Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 16

  8. Percentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 16

    Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 16

  9. Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 16

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

    Time frame: Week 16

  10. Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 16

    Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Up to Week 16. (At Baseline, subjects were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)

  11. Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 16

    Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 16

  12. Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/16

    Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)

  13. Change From Baseline in Fecal Calprotectin Level Over Time During the Induction Phase

    Time frame: Baseline, Week 4, Week 16

  14. Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16

    Time frame: Baseline, Week 16

  15. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Over Time During the Induction Phase

    The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life.

    Time frame: Baseline, Week 8, Week 16

  16. Percentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 16

    Remission is defined as endoscopic remission AND clinical remission. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Week 16

  17. Percentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 16

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission and a score above 450 indicates very severe disease.

    Time frame: Week 16

  18. Percentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/16

    Endoscopic remission: SES-CD ≤ 4 and at least two point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)

  19. Percentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline

    Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 16

  20. Change From Baseline in Abdominal Pain Rating Scale at Week 12

    Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).

    Time frame: Baseline, Week 12

  21. Change From Baseline in Abdominal Pain Rating Scale at Week 16

    Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).

    Time frame: Baseline, Week 16

  22. Percentage of Participants Who Achieve Remission at Week 52

    Remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record. See definitions of responder and clinical responder in Outcome Measure 7 of this record.

    Time frame: Week 52

  23. Percentage of Participants Who Achieve Endoscopic Remission at Week 52

    Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Week 52

  24. Percentage of Participants Who Achieve Both Endoscopic Remission and Modified Clinical Remission at Week 52 Among Subjects With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

    Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus induction baseline and no subscore \> 1 in any individual variable. Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.

    Time frame: Week 52

  25. Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase in Participants Receiving Upadacitinib in Induction

    Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  26. Percentage of Participants Who Maintain Clinical Remission Over Time Among Participants in Clinical Remission at Week 16 in Participants Receiving Upadacitinib in Induction

    Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  27. Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

    Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  28. Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants In Modified Clinical Remission At Week 16 and Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

    Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  29. Percentage of Participants Who Achieve Response at Week 52

    Response at Week 52 was defined as both endoscopic response at Week 52 and clinical response at Week 52. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Week 52

  30. Percentage of Participants With SES-CD ≤ 2 at Week 52

    SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  31. Percentage of Participants With SES-CD = 0 at Week 52

    SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  32. Percentage of Participants Who Achieve Endoscopic Response at Week 52

    Endoscopic response was defined as SES-CD at least 25% reduction from Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  33. Percentage of Participants Who Achieve Enhanced Endoscopic Response at Week 52

    Enhanced endoscopic response was defined as SES-CD reduction from Induction Baseline \> 50% (or for an Induction Baseline SES-CD of 4, at least a 2 point reduction from Induction Baseline). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  34. Percentage of Participants Who Achieve Endoscopic Improvement at Week 52

    Endoscopic Improvement: SES-CD reduction from Induction Baseline \> 50% or endoscopic remission. Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  35. Percentage of Participants Who Achieve Endoscopic Healing at Week 52

    Endoscopic healing was defined as SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore \>= 1 at Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

    Time frame: Week 52

  36. Percentage of Participants Who Achieve Clinical Response Over Time During Extension Phase

    Clinical response was defined as average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  37. Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase

    Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  38. Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase Among Participants In Enhanced Clinical Response At Week 16

    Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline or average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  39. Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase Among Participants With an Average Daily Stool Frequency ≥ 2.5 and Average Daily Abdominal Pain ≥ 2.0 at Induction Baseline

    Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  40. Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 Over Time

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  41. Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Remission At Week 52

    Steroid-free remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2 point reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Clinical remission: Average daily stool frequency ≤ 1.5 and not worse than baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.

    Time frame: Baseline, Week 52

  42. Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission Over Time

    Steroid-free clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  43. Percentage of Participants Taking Corticosteroids at Induction Baseline and With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Modified Clinical Remission Over Time

    Steroid-free modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  44. Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 52

    Steroid-free endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Baseline, Week 52

  45. Percentage Of Participants Who Achieve CDAI < 150 Over Time During Extension Phase

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  46. Percentage of Participants With Decrease in CDAI ≥ 70 Points From Induction Baseline Over Time During Extension Phase

    CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.

    Time frame: Week 20, Week 28, Week 36, Week 44, Week 52

  47. Change From Induction Baseline in Fecal Calprotectin Level Over Time During Extension Phase

    Time frame: Baseline, Week 28, Week 52

  48. Change From Induction Baseline in Hs-CRP Over Time During Extension Phase

    Time frame: Baseline, Week 20, Week 28, Week 36, Week 44, Week 52

  49. Change From Induction Baseline in IBDQ at Week 52

    The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function, and social function. Each subscale can be computed with total scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.

    Time frame: Baseline, Week 52

  50. Change From Induction Baseline in European Quality of Life (EuroQol) 5 Dimensions Questionnaire (EQ-5D) Index Score at Week 52

    The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. A positive change represents an improvement in health-related quality of life.

    Time frame: Baseline, Week 52

  51. Change From Induction Baseline in EQ-5D VAS at Week 52

    The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in health-related quality of life.

    Time frame: Baseline, Week 52

  52. Cross Tabulation of Induction Baseline and Week 52 in Total Number of Extra-Intestinal Manifestations (EIMs) of Crohn's Disease

    Presented as percentage of participants with given number of EIMs at Baseline (BL) and Week (Wk) 52. EIMs of Crohn's disease included anemia, autoimmune hepatitis, axial arthropathy, bronchiectasis, chronic obstructive pulmonary disease, episcleritis, erythema nodosum, iritis, nephrolithiasis, oral aphthous ulcers, peripheral arthropathy, primary sclerosing cholangitis, pyoderma gangrenosum, Sweet's syndrome, uveitis, and venous thromboembolism.

    Time frame: Baseline, Week 52

  53. Percentage of Participants Who Achieve Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline

    Remission at Week 52 is defined as endoscopic remission at Week 52 AND clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

    Time frame: Baseline, Week 52

  54. Percentage of Participants Who Achieve Modified Clinical Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline And Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

    Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

    Time frame: Week 52

07

Results

Posted Aug 14, 2023

Participant flow

Double-Blind Induction (Weeks 1-16)
Participant flow — Double-Blind Induction (Weeks 1-16)
MilestoneDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDDouble Blind Extension Phase: Upadacitinib 3 mg BIDDouble Blind Extension Phase: Upadacitinib 6 mg BIDDouble Blind Extension Phase: Upadacitinib 12 mg BIDDouble Blind Extension Phase: Upadacitinib 24 mg QD
Started3739373636350000
Completed2734332729300000
Not completed10549750000
Withdrew: Requires alternative therapy0001000000
Withdrew: Adverse event3407120000
Withdrew: Lack of efficacy3111210000
Withdrew: Other1010110000
Withdrew: Withdrawal by subject2010200000
Withdrew: Subject non-compliance1000110000
Withdrew: Lost to follow-up0010000000
Double-Blind Extension (Weeks 16-52)
Participant flow — Double-Blind Extension (Weeks 16-52)
MilestoneDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDDouble Blind Extension Phase: Upadacitinib 3 mg BIDDouble Blind Extension Phase: Upadacitinib 6 mg BIDDouble Blind Extension Phase: Upadacitinib 12 mg BIDDouble Blind Extension Phase: Upadacitinib 24 mg QD
Started00000061235937
Switched to ol 12 mg bid0000002151717
Further dose escalated to ol 24 mg bid000000521010
Dose de-escalated to ol 12 mg bid0000000000
Completed00000043214322
Not completed0000001821615
Withdrew: Requires alternative therapy0000002000
Withdrew: Adverse event0000006044
Withdrew: Lack of efficacy00000072810
Withdrew: Withdrawal by subject0000001021
Withdrew: Subject noncompliance0000002020

Outcome measures

PrimaryPercentage of Participants Who Achieve Endoscopic Remission at Week 12/16

Endoscopic remission was determined using Simplified Endoscopic Score for Crohn's Disease (SES-CD). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable.

Time frame:
Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16010.38.18.322.214.3
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.056 (Statistical significance was prespecified at α = 0.1. Based on Cochran-Mantel-Haenszel (CMH) test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 9.9 · 95% CI -0.3 to 20.1
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.108 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 7.4 · 95% CI -1.6 to 16.4
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.099 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 7.7 · 95% CI -1.5 to 16.8
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.004 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 21 · 95% CI 6.8 to 35.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.025 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.6 · 95% CI 1.8 to 25.5
PrimaryPercentage of Participants Who Achieve Clinical Remission at Week 16

Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Clinical Remission at Week 1610.812.827.011.122.214.3
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.74 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 2.5 · 95% CI -12.3 to 17.3
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.082 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 16.2 · 95% CI -2.0 to 34.3
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.952 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 0.5 · 95% CI -14.1 to 15.0
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.205 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 11.2 · 95% CI -6.1 to 28.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.607 (Statistical significance was prespecified at α = 0.1. Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 4.1 · 95% CI -11.5 to 19.6
SecondaryPercentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 16

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Crohn's Disease Activity Index (CDAI) < 150 at Week 1616.220.529.738.930.620.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.564 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 5.2 · 95% CI -12.5 to 22.9
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.221 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12 · 95% CI -7.2 to 31.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.036 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 22.2 · 95% CI 1.4 to 43
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.179 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.4 · 95% CI -6.2 to 33.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.677 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.9 · 95% CI -14.3 to 22
SecondaryPercentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 16

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants With a Decrease in CDAI ≥ 70 Points From Baseline at Week 1635.146.254.144.461.148.6
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.363 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 10.4 · 95% CI -12 to 32.9
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.137 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 17.3 · 95% CI -5.5 to 40
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.512 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 7.5 · 95% CI -14.9 to 29.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.035 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 25 · 95% CI -1.8 to 48.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.29 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12.5 · 95% CI -10.7 to 35.6
SecondaryPercentage of Participants Who Achieve Clinical Remission at Week 12

Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Remission at Week 12
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Clinical Remission at Week 1210.810.329.713.925.08.6
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.896 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: -0.9 · 95% CI -15.0 to 13.1
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.05 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 18.6 · 95% CI 0.0 to 37.3
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.702 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.0 · 95% CI -12.4 to 18.4
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.117 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 14.3 · 95% CI -3.6 to 32.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.736 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: -2.4 · 95% CI -16.4 to 11.6
SecondaryPercentage of Participants Who Achieve Remission at Week 16

Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Remission at Week 160.02.65.42.88.35.7
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.276 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 2.9 · 95% CI -2.3 to 8.1
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.195 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 4.9 · 95% CI -2.5 to 12.4
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.355 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 2.6 · 95% CI -2.9 to 8.0
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.099 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 7.7 · 95% CI -1.5 to 16.8
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.185 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 5.2 · 95% CI -2.5 to 12.9
SecondaryPercentage of Participants Who Achieve Response at Week 16

Response is defined as endoscopic response at Week 12/16 AND clinical response at Week 16. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Response at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Response at Week 162.715.432.427.838.934.3
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.05 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.2 · 95% CI 0.0 to 26.5
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 29.5 · 95% CI 11.9 to 47.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.003 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 25.2 · 95% CI 8.5 to 42.0
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = < 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 36.5 · 95% CI 17.6 to 55.4
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = < 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 32.0 · 95% CI 13.9 to 50.2
SecondaryPercentage of Participants With Endoscopic Response at Week 12/16

Endoscopic response: SES-CD at least 25% reduction from Baseline. Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Up to Week 16 (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 12/16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants With Endoscopic Response at Week 12/1613.523.143.236.150.048.6
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.243 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 10.5 · 95% CI -7.2 to 28.2
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.006 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 29.1 · 95% CI 8.3 to 49.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.017 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 24.2 · 95% CI 4.4 to 44.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = < 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 36.5 · 95% CI 14.8 to 58.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = < 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 36.8 · 95% CI 15.2 to 58.3
SecondaryPercentage of Participants Who Achieve Clinical Response at Week 16

Clinical response: average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain not worse than Baseline OR average daily abdominal pain at least 30% reduction from Baseline and average daily stool frequency not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Response at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Clinical Response at Week 1632.443.656.847.261.148.6
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.353 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 10.5 · 95% CI -11.7 to 32.7
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.05 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 22.7 · 95% CI 0.0 to 45.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.268 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12.5 · 95% CI -9.6 to 34.6
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.018 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 28.0 · 95% CI 4.8 to 51.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.204 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 14.9 · 95% CI -8.1 to 37.8
SecondaryPercentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 16

Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants With an Average Daily Stool Frequency ≥ 2.5 AND Average Daily Abdominal Pain ≥ 2.0 at Baseline Who Achieve Clinical Remission at Week 167.117.618.816.725.011.1
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.421 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 10.0 · 95% CI -14.4 to 34.4
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.371 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 11.5 · 95% CI -13.8 to 36.8
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.445 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 9.2 · 95% CI -14.4 to 32.8
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.198 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 19.5 · 95% CI -10.2 to 49.3
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.654 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 5.0 · 95% CI -17.0 to 27.0
SecondaryPercentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 16

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 at Week 160.019.022.241.233.310.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.093 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 18.7 · 95% CI -3.1 to 40.5
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.176 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.5 · 95% CI -6.1 to 33.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.017 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 35.9 · 95% CI 6.3 to 65.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.044 · Adjusted risk difference from placebo: 26.1 · 95% CI 0.7 to 51.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.121 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.1 · 95% CI -3.5 to 29.6
SecondaryPercentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 16

Remission is defined as endoscopic remission at Week 12/16 AND clinical remission at Week 16. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Up to Week 16. (At Baseline, subjects were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Remission at Week 12/16 and Clinical Remission at Week 160.00.05.65.913.30.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.564 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.4 · 95% CI -8.1 to 14.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.584 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.4 · 95% CI -8.8 to 15.7
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.326 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 8.7 · 95% CI -8.7 to 26.1
SecondaryPercentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 16

Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission at Week 160.014.322.211.833.310.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.195 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12.2 · 95% CI -6.2 to 30.7
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.116 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 17.9 · 95% CI -4.4 to 40.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.178 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12.8 · 95% CI -5.8 to 31.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.031 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 30.4 · 95% CI 2.8 to 58.0
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.121 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.1 · 95% CI -3.5 to 29.6
SecondaryPercentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/16

Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Taking Corticosteroids at Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 12/160.00.011.15.920.010.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.392 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 6.8 · 95% CI -8.7 to 22.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.584 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.4 · 95% CI -8.8 to 15.7
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.199 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.0 · 95% CI -6.8 to 32.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.439 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 6.9 · 95% CI -10.6 to 24.5
SecondaryChange From Baseline in Fecal Calprotectin Level Over Time During the Induction Phase
Time frame:
Baseline, Week 4, Week 16
Reported as:
Mean · μg/g
Change From Baseline in Fecal Calprotectin Level Over Time During the Induction Phase
μg/gDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Week 483.7 ± 1024.11-310.3 ± 2415.43-436.9 ± 1505.75-915.7 ± 1600.31-876.2 ± 2240.93-255.8 ± 2407.47
Week 16-128.9 ± 373.53-534.5 ± 3279.19-429.4 ± 2505.21-475.1 ± 2668.93-828.7 ± 986.09-698.4 ± 2228.85
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.788 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -103.9 · 95% CI -865.69 to 657.87
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.325 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -364.3 · 95% CI -1092.83 to 364.29
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.015 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -926.2 · 95% CI -1672.78 to -179.63
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.053 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -763.1 · 95% CI -1534.52 to 8.39
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.352 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -359.5 · 95% CI -1119.52 to 400.56
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.503 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -396.2 · 95% CI -1565.39 to 772.90
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.537 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -364.3 · 95% CI -1531.04 to 802.44
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.425 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -483.2 · 95% CI -1677.87 to 711.52
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.134 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1025.6 · 95% CI -2373.24 to 322.08
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.293 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -637.9 · 95% CI -1833.82 to 557.96
SecondaryChange From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16
Time frame:
Baseline, Week 16
Reported as:
Mean · mg/L
Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16
mg/LDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 16-0.1 ± 11.96-3.0 ± 19.60-3.9 ± 19.47-6.1 ± 27.02-14.8 ± 26.38-2.7 ± 13.74
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.921 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 0.5 · 95% CI -9.02 to 9.97
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.75 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.6 · 95% CI -11.19 to 8.08
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.7 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.9 · 95% CI -11.7 to 7.87
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.024 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -11.4 · 95% CI -21.38 to -1.51
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.845 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.0 · 95% CI -10.72 to 8.79
SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Over Time During the Induction Phase

The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life.

Time frame:
Baseline, Week 8, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Over Time During the Induction Phase
units on a scaleDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Week 816.6 ± 25.3818.9 ± 40.3534.6 ± 36.2224.9 ± 30.9539.7 ± 40.7623.3 ± 30.34
Week 1614.5 ± 29.1524.6 ± 42.9841.8 ± 47.0232.1 ± 38.5744.4 ± 40.0522.5 ± 27.82
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.830 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 1.7 · 95% CI -13.60 to 16.92
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.027 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 17.5 · 95% CI 2.03 to 33.00
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.263 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 8.9 · 95% CI -6.72 to 24.47
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.008 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 21.6 · 95% CI 5.68 to 37.52
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.269 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 8.8 · 95% CI -6.88 to 24.53
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.231 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 10.3 · 95% CI -6.63 to 27.25
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.002 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 27.9 · 95% CI 10.68 to 45.15
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.057 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 17.1 · 95% CI -0.51 to 34.72
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.002 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 28.8 · 95% CI 11.12 to 46.56
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.165 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 12.3 · 95% CI -5.12 to 29.72
SecondaryPercentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 16

Remission is defined as endoscopic remission AND clinical remission. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants With Isolated Ileal Crohn's Disease at Baseline Who Achieve Remission at Week 160.020.016.720.00.020.0
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.167 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 20.0 · 95% CI -8.4 to 48.4
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.221 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 16.7 · 95% CI -10.0 to 43.3
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.18 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 20.0 · 95% CI -9.2 to 49.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.167 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Ls mean difference: 20.0 · 95% CI -8.4 to 48.4
SecondaryPercentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 16

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission and a score above 450 indicates very severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants With a Decrease in CDAI ≥ 100 Points From Baseline at Week 1627.033.340.544.455.631.4
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.607 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 5.5 · 95% CI -15.5 to 26.5
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.272 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 12.2 · 95% CI -9.6 to 33.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = -0.157 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 15.9 · 95% CI -6.1 to 37.9
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.017 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Ls mean difference: 27.7 · 95% CI 4.9 to 50.6
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.798 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 2.8 · 95% CI -18.4 to 23.9
SecondaryPercentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/16

Endoscopic remission: SES-CD ≤ 4 and at least two point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Up to Week 16. (At Baseline, participants were allocated by randomization 1:1 to have their end of induction colonoscopy done at either Week 12 or Week 16; this endpoint combines the two time points.)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/16
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve > 50% Reduction From Baseline in SES-CD or Endoscopic Remission at Week 12/162.712.818.925.036.125.7
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.119 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 9.8 · 95% CI -2.5 to 22.1
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.034 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 15.4 · 95% CI 1.1 to 29.7
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.004 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 23.2 · 95% CI 7.3 to 39.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = < 0.001 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 32.4 · 95% CI 14.2 to 50.5
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = < 0.006 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 22.9 · 95% CI 6.6 to 39.2
SecondaryPercentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline

Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Percentage of Participants Who Achieve Modified Clinical Remission at Week 16 Among Participants With an Average Daily Stool Frequency ≥ 4.0 or Average Daily Abdominal Pain ≥ 2.0 at Baseline12.115.830.326.536.718.8
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · Cochran-Mantel-Haenszel · p = 0.647 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 3.9 · 95% CI -12.7 to 20.5
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · Cochran-Mantel-Haenszel · p = 0.093 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 17.1 · 95% CI -2.9 to 37.1
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · Cochran-Mantel-Haenszel · p = 0.165 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 13.6 · 95% CI -5.6 to 32.8
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · Cochran-Mantel-Haenszel · p = 0.023 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 24.9 · 95% CI 3.4 to 46.3
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · Cochran-Mantel-Haenszel · p = 0.448 (Based on CMH test stratified by baseline SES-CD (SES-CD \<15 and SES-CD \>=15).) · Adjusted risk difference from placebo: 7.0 · 95% CI -11.0 to 25.0
SecondaryChange From Baseline in Abdominal Pain Rating Scale at Week 12

Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Abdominal Pain Rating Scale at Week 12
units on a scaleDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Change From Baseline in Abdominal Pain Rating Scale at Week 12-1.1 ± 1.84-1.0 ± 2.61-2.6 ± 2.53-2.4 ± 3.17-2.7 ± 2.52-1.0 ± 1.99
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.412 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 0.4 · 95% CI -0.62 to 1.5
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.01 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.4 · 95% CI -2.47 to -0.34
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.082 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.0 · 95% CI -2.13 to 0.13
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.004 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.6 · 95% CI -2.73 to -0.52
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.766 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: 0.2 · 95% CI -0.93 to 1.26
SecondaryChange From Baseline in Abdominal Pain Rating Scale at Week 16

Abdominal pain was assessed on an abdominal pain rating scale, where subjects rated their average abdominal pain over the last 24 hours on a scale of 0 (none) to 10 (worst pain imaginable).

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Abdominal Pain Rating Scale at Week 16
units on a scaleDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QD
Change From Baseline in Abdominal Pain Rating Scale at Week 16-0.9 ± 2.27-1.7 ± 3.02-2.8 ± 2.77-1.7 ± 2.86-2.3 ± 2.42-1.4 ± 2.15
Statistical analysis
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 3 mg BID · mixed-effect model repeated measure · p = 0.314 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -0.6 · 95% CI -1.75 to 0.56
  • Double-Blind Induction Phase: Placebo BID vs Double-Blind Induction Phase: Upadacitinib 6 mg BID · mixed-effect model repeated measure · p = 0.002 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.8 · 95% CI -3.01 to -0.68
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 12 mg BID · mixed-effect model repeated measure · p = 0.255 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -0.7 · 95% CI -1.94 to 0.52
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg BID · mixed-effect model repeated measure · p = 0.022 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -1.4 · 95% CI -2.61 to -0.2
  • Double-Blind Induction Phase: Placebo BID vs Double Blind Induction Phase: Upadacitinib 24 mg QD · mixed-effect model repeated measure · p = 0.239 (P value for test of difference using the repeated measure model including treatment, Baseline disease severity (SES-CD \< 15 and ≥ 15), week, Baseline, interaction of treatment and week.) · Ls mean difference: -0.7 · 95% CI -1.92 to 0.48
SecondaryPercentage of Participants Who Achieve Remission at Week 52

Remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record. See definitions of responder and clinical responder in Outcome Measure 7 of this record.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Remission at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/Placebo in InductionUpadacitinib 6 mg BID in Extension/Placebo in InductionUpadacitinib 12 mg BID in Extension/Placebo in InductionUpadacitinib 24 mg QD in Extension/Placebo in Induction
Responders20.012.525.00.00.0———
Non-Responders0.00.02.913.00.00.00.025.0
Clinical Responders12.57.113.815.80.00.00.0100
Clinical Non-Responders0.00.04.80.00.00.00.00.0
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -7.5 · 95% CI -36.4 to 21.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -22.5 to 32.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/Upadacitinib in Induction · Chi-squared · p = 0.272 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -37.5 to -2.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 2.9 · 95% CI -2.7 to 8.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/Upadacitinib in Induction · Chi-squared · p = 0.068 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 13.0 · 95% CI -0.7 to 26.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.0000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -5.4 · 95% CI -23.1 to 12.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 1.3 · 95% CI -15.7 to 18.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 3.3 · 95% CI -16.7 to 23.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/Upadacitinib in Induction · Chi-squared · p = 1.000 (P value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.8 · 95% CI -4.3 to 13.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
SecondaryPercentage of Participants Who Achieve Endoscopic Remission at Week 52

Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Endoscopic Remission at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders25.025.037.510.00———
Non-Responders3.110.08.817.400025.0
Clinical Responders15.621.424.126.3000100
Clinical Non-Responders5.009.500000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -35.5 to 35.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.483 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -17.9 to 42.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.633 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -41.6 to 11.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.424 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.9 · 95% CI -12.7 to 26.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.614 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.7 · 95% CI -5.6 to 17.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.149 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.3 · 95% CI -2.4 to 30.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.684 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.8 · 95% CI -19.1 to 30.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.404 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.5 · 95% CI -11.5 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.470 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.7 · 95% CI -12.8 to 34.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.5 · 95% CI -11.3 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Both Endoscopic Remission and Modified Clinical Remission at Week 52 Among Subjects With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus induction baseline and no subscore \> 1 in any individual variable. Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both Endoscopic Remission and Modified Clinical Remission at Week 52 Among Subjects With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders29.412.533.310.00———
Non-responders006.115.000025.0
Clinical responders17.97.122.222.2000100
Clinical non-responders004.800000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.624 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.9 · 95% CI -48.4 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.9 · 95% CI -28.3 to 36.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.363 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -19.4 · 95% CI -48.0 to 9.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.495 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.1 · 95% CI -2.1 to 14.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.066 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significance at the 0.1 level.) · Risk difference (rd): 15.0 · 95% CI -0.6 to 30.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.645 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -30.3 to 8.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -16.8 to 25.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.721 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -19.5 to 28.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.8 · 95% CI -4.3 to 13.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase in Participants Receiving Upadacitinib in Induction

Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase in Participants Receiving Upadacitinib in Induction
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in Induction
Responders, Week 2045.037.550.040.0
Responders, Week 2845.037.556.350.0
Responders, Week 3640.037.562.530.0
Responders, Week 4440.012.568.840.0
Responders, Week 5230.037.562.530.0
Non-responders, Week 2012.540.08.88.7
Non-responders, Week 2812.540.08.813.0
Non-responders, Week 369.410.02.913.0
Non-responders, Week 4412.520.05.98.7
Non-responders, Week 529.410.08.813.0
Clinical responders, Week 2040.650.037.931.6
Clinical responders, Week 2837.550.041.442.1
Clinical responders, Week 3634.428.637.931.9
Clinical responders, Week 4434.421.444.831.6
Clinical responders, Week 5225.028.641.431.6
Clinical non-responders, Week 200000
Clinical non-responders, Week 285.0000
Clinical non-responders, Week 360000
Clinical non-responders, Week 445.0000
Clinical non-responders, Week 525.004.80
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.5 · 95% CI -47.5 to 32.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.765 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -27.8 to 37.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -42.4 to 32.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.5 · 95% CI -47.5 to 32.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.502 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.3 · 95% CI -21.4 to 43.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -32.9 to 42.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.5 · 95% CI -42.3 to 37.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.180 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 22.5 · 95% CI -9.5 to 54.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.702 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -45.6 to 25.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.214 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -27.5 · 95% CI -58.9 to 3.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.086 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 28.8 · 95% CI -2.5 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -37.2 to 37.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.5 · 95% CI -31.6 to 46.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.051 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 32.5 · 95% CI 1.4 to 63.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -34.8 to 34.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.075 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 27.5 · 95% CI -5.0 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.705 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.7 · 95% CI -18.6 to 11.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.8 · 95% CI -20.0 to 12.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.075 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 27.5 · 95% CI -5.0 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.705 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.7 · 95% CI -18.6 to 11.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.5 · 95% CI -17.4 to 18.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.6 · 95% CI -20.5 to 21.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.348 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.4 · 95% CI -18.0 to 5.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.7 · 95% CI -13.4 to 20.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.616 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.5 · 95% CI -19.8 to 34.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.420 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.6 · 95% CI -20.5 to 7.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.8 · 95% CI -20.0 to 12.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.6 · 95% CI -20.5 to 21.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.6 · 95% CI -14.4 to 13.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.7 · 95% CI -13.4 to 20.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.555 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 9.4 · 95% CI -21.9 to 40.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.830 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.7 · 95% CI -27.2 to 21.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.518 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -9.0 · 95% CI -36.0 to 17.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.428 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -18.6 to 43.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.757 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.9 · 95% CI -20.7 to 28.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.745 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.6 · 95% CI -23.2 to 32.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.8 · 95% CI -34.6 to 23.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.773 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.6 · 95% CI -20.6 to 27.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.838 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.8 · 95% CI -29.4 to 23.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.497 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.9 · 95% CI -40.0 to 14.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.404 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.5 · 95% CI -14.0 to 34.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.838 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.8 · 95% CI -29.4 to 23.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.6 · 95% CI -24.4 to 31.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.174 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.4 · 95% CI -7.0 to 39.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.611 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.6 · 95% CI -19.1 to 32.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.488 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.488 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.2 · 95% CI -13.4 to 13.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Maintain Clinical Remission Over Time Among Participants in Clinical Remission at Week 16 in Participants Receiving Upadacitinib in Induction

Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintain Clinical Remission Over Time Among Participants in Clinical Remission at Week 16 in Participants Receiving Upadacitinib in Induction
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in Induction
Responders, Week 2080.066.771.4100
Responders, Week 2890.066.757.1100
Responders, Week 3680.010071.466.7
Responders, Week 4480.033.371.466.7
Responders, Week 5260.066.771.466.7
Non-responders, Week 2066.710050.0100
Non-responders, Week 2866.710050.0100
Non-responders, Week 3666.733.350.0100
Non-responders, Week 4466.766.750.0100
Non-responders, Week 5233.333.30100
Clinical responders, Week 2076.983.366.7100
Clinical responders, Week 2884.683.355.6100
Clinical responders, Week 3676.966.766.775.0
Clinical responders, Week 4476.950.066.775.0
Clinical responders, Week 5253.850.055.675.0
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -72.2 to 45.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.6 · 95% CI -50.2 to 33.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -4.8 to 44.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.423 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -23.3 · 95% CI -79.8 to 33.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.250 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -32.9 · 95% CI -74.0 to 8.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -8.6 to 28.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -4.8 to 44.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.6 · 95% CI -50.2 to 33.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -72.2 to 45.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.203 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -46.7 · 95% CI -100.0 to 12.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.6 · 95% CI -50.2 to 33.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -72.2 to 45.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.7 · 95% CI -54.7 to 68.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.4 · 95% CI -33.8 to 56.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.7 · 95% CI -54.7 to 68.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -100.0 to 42.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -75.4 to 75.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -75.4 to 75.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -86.7 to 20.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 66.7 · 95% CI 13.3 to 100.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.4 · 90% CI -31.2 to 44.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.655 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.3 · 95% CI -48.6 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.541 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.1 · 95% CI 0.2 to 46.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.3 · 95% CI -37.0 to 34.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.178 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -29.1 · 95% CI -67.0 to 8.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.4 · 95% CI -4.2 to 35.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.3 · 95% CI -54.4 to 33.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.655 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.3 · 95% CI -48.6 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.9 · 95% CI -50.1 to 46.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.320 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -26.9 · 95% CI -73.0 to 19.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.655 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.3 · 95% CI -48.6 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.9 · 95% CI -50.1 to 46.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.8 · 95% CI -52.2 to 44.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.7 · 95% CI -40.6 to 44.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.603 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.2 · 95% CI -29.2 to 71.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2047.162.566.760.00———
Responders, Week 2870.650.066.760.00———
Responders, Week 3658.887.573.330.00———
Responders, Week 4447.137.573.340.00———
Responders, Week 5241.262.573.340.00———
Non-responders, Week 2017.944.412.110.042.920.025.025.0
Non-responders, Week 2821.444.49.115.042.920.025.050.0
Non-responders, Week 3614.311.16.115.057.120.025.025.0
Non-responders, Week 4414.322.26.110.042.920.037.525.0
Non-responders, Week 527.111.112.115.028.6037.550.0
Clinical responders, Week 2042.964.351.944.460.010033.3100
Clinical responders, Week 2857.157.148.150.060.010033.3100
Clinical responders, Week 3646.457.148.133.380.010033.3100
Clinical responders, Week 4439.335.748.133.360.010033.3100
Clinical responders, Week 5228.642.951.938.940.0033.3100
Clinical non-responders, Week 205.90000020.00
Clinical non-responders, Week 2811.80000020.033.3
Clinical non-responders, Week 365.90000020.00
Clinical non-responders, Week 445.90000040.00
Clinical non-responders, Week 525.904.800040.033.3
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.673 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.4 · 95% CI -25.6 to 56.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.265 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 19.6 · 95% CI -14.0 to 53.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.695 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.9 · 95% CI -25.6 to 51.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.394 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.6 · 95% CI -61.4 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.9 · 95% CI -36.1 to 28.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.683 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.6 · 95% CI -47.9 to 26.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.205 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 28.7 · 95% CI -4.1 to 61.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.388 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.5 · 95% CI -17.9 to 46.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.236 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -28.8 · 95% CI -65.6 to 8.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -9.6 · 95% CI -50.6 to 31.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.131 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.3 · 95% CI -6.3 to 58.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.1 · 95% CI -45.6 to 31.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.411 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.3 · 95% CI -19.6 to 62.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.067 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 32.2 · 95% CI -0.2 to 64.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.2 · 95% CI -39.5 to 37.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.178 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.6 · 95% CI -8.8 to 62.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.720 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.7 · 95% CI -23.8 to 12.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.683 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.9 · 95% CI -27.2 to 11.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.215 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.0 · 95% CI -12.8 to 58.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.279 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.3 · 95% CI -30.4 to 5.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.716 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.4 · 95% CI -28.2 to 15.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.2 · 95% CI -27.5 to 21.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.400 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.2 · 95% CI -23.5 to 7.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.7 · 95% CI -19.6 to 21.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.620 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.9 · 95% CI -22.2 to 38.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.400 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.2 · 95% CI -23.5 to 7.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.3 · 95% CI -22.7 to 14.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.0 · 95% CI -18.7 to 26.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.678 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -9.7 to 19.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.636 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.9 · 95% CI -10.5 to 26.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.190 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.4 · 95% CI -9.7 to 52.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.504 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 9.0 · 95% CI -17.3 to 35.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.916 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.6 · 95% CI -27.8 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -31.7 to 31.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.504 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -9.0 · 95% CI -35.3 to 17.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.635 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.1 · 95% CI -36.6 to 22.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.513 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.7 · 95% CI -21.1 to 42.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.898 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.7 · 95% CI -24.7 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.379 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.1 · 95% CI -41.7 to 15.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.822 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.6 · 95% CI -34.5 to 27.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.508 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.9 · 95% CI -17.3 to 35.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.683 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.0 · 95% CI -34.3 to 22.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.490 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.3 · 95% CI -16.6 to 45.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.078 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 23.3 · 95% CI -1.9 to 48.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.466 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.3 · 95% CI -17.7 to 38.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.447 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.8 · 95% CI -27.1 to 3.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.193 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.8 · 95% CI -27.1 to 3.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.498 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.8 · 95% CI -27.1 to 3.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.447 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.447 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.1 · 95% CI -15.5 to 13.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.9 · 95% CI -17.1 to 5.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants In Modified Clinical Remission At Week 16 and Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline and average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Modified Clinical Remission Over Time During Extension Phase Among Participants In Modified Clinical Remission At Week 16 and Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2066.760.090.0100————
Responders, Week 2891.760.090.0100————
Responders, Week 3666.710090.075.0————
Responders, Week 4466.740.090.075.0————
Responders, Week 5258.380.090.075.0————
Non-responders, Week 2066.780.050.0100100—100100
Non-responders, Week 2810060.050.0100100—100100
Non-responders, Week 3666.720.050.0100100—100100
Non-responders, Week 4466.740.050.010050.0—100100
Non-responders, Week 5233.320.050.010050.0—100100
Clinical responders, Week 2066.770.083.3100100—100100
Clinical responders, Week 2893.360.083.3100100—100100
Clinical responders, Week 3666.760.083.380.0100—100100
Clinical responders, Week 4466.740.083.380.050.0—100100
Clinical responders, Week 5253.350.083.380.050.0—100100
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.7 · 95% CI -57.2 to 43.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.323 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -9.2 to 55.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.516 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI 6.7 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.191 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -31.7 · 95% CI -77.4 to 14.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -26.0 to 22.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -7.3 to 24.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.261 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI 6.7 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.323 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -9.2 to 55.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -41.8 to 58.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.593 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -26.7 · 95% CI -77.2 to 23.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.323 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -9.2 to 55.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -41.8 to 58.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.600 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.7 · 95% CI -23.1 to 66.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.162 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 31.7 · 95% CI -1.9 to 65.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -34.1 to 67.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -50.5 to 77.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.464 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -40.0 · 95% CI -82.9 to 2.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.400 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -100.0 to 19.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.464 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -46.7 · 95% CI -100.0 to 17.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -26.7 · 95% CI -95.1 to 41.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -100.0 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -77.2 to 50.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -70.8 to 100.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 66.7 · 95% CI 13.3 to 100.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.3 · 95% CI -33.8 to 40.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.408 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -15.2 to 48.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.266 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI 9.5 to 57.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.121 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -66.2 to -0.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = -10.0 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -34.6 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.7 · 95% CI -6.0 to 19.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.7 · 95% CI -45.3 to 31.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.408 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -15.2 to 48.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -29.1 to 55.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.241 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -26.7 · 95% CI -65.3 to 11.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.408 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -15.2 to 48.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -29.1 to 55.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.3 · 95% CI -43.3 to 36.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.217 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 30.0 · 95% CI -2.9 to 62.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.603 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.7 · 95% CI -16.5 to 69.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Response at Week 52

Response at Week 52 was defined as both endoscopic response at Week 52 and clinical response at Week 52. Endoscopic response: SES-CD at least 25% reduction from Baseline. Clinical response: average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Response at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders50.062.568.840.0100———
Non-responders6.310.014.713.0020.022.225.0
Clinical responders34.442.951.736.816.700100
Clinical non-responders5.004.80025.040.00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -27.6 to 52.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.257 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.8 · 95% CI -12.8 to 50.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.709 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -47.4 to 27.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.7 · 95% CI -16.6 to 24.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.428 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.5 · 95% CI -6.1 to 23.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.639 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.8 · 95% CI -9.3 to 22.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.583 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.5 · 95% CI -22.2 to 39.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.171 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 17.3 · 95% CI -7.2 to 41.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.859 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.5 · 95% CI -24.8 to 29.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.2 · 95% CI -13.4 to 13.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants With SES-CD ≤ 2 at Week 52

SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With SES-CD ≤ 2 at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders10.012.531.300———
Non-responders6.308.88.700025.0
Clinical responders6.37.120.710.5000100
Clinical non-responders10.009.500000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.5 · 95% CI -23.9 to 28.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.204 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.3 · 95% CI -5.0 to 47.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.540 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.3 · 95% CI -14.6 to 2.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.6 · 95% CI -10.1 to 15.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.4 · 95% CI -11.8 to 16.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.9 · 95% CI -15.0 to 16.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.135 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.4 · 95% CI -2.5 to 31.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.623 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.3 · 95% CI -11.9 to 20.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.5 · 95% CI -18.7 to 17.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.501 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants With SES-CD = 0 at Week 52

SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With SES-CD = 0 at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders10.012.531.300———
Non-responders3.108.84.30000
Clinical responders6.37.120.75.30000
Clinical non-responders5.009.500000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.5 · 95% CI -23.9 to 28.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.204 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.3 · 95% CI -5.0 to 47.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.540 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.1 · 95% CI -9.2 to 2.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.614 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.7 · 95% CI -5.6 to 17.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.2 · 95% CI -9.1 to 11.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.9 · 95% CI -15.0 to 16.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.135 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.4 · 95% CI -2.5 to 31.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.0 · 95% CI -14.1 to 12.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.5 · 95% CI -11.3 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Endoscopic Response at Week 52

Endoscopic response was defined as SES-CD at least 25% reduction from Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Endoscopic Response at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders60.075.075.040.0100———
Non-responders15.620.020.617.4020.022.225.0
Clinical responders40.657.155.242.116.700100
Clinical non-responders20.0014.30025.040.00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.669 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.0 · 95% CI -21.9 to 51.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.343 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.0 · 95% CI -15.2 to 45.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.442 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -57.2 to 17.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -23.4 to 32.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.601 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -13.6 to 23.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.8 · 95% CI -18.2 to 21.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.301 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.5 · 95% CI -14.5 to 47.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.256 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 14.5 · 95% CI -10.3 to 39.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.917 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.5 · 95% CI -26.5 to 29.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.2 · 95% CI -37.5 to -2.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.697 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.7 · 95% CI -28.8 to 17.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.126 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -37.5 to -2.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Enhanced Endoscopic Response at Week 52

Enhanced endoscopic response was defined as SES-CD reduction from Induction Baseline \> 50% (or for an Induction Baseline SES-CD of 4, at least a 2 point reduction from Induction Baseline). SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Enhanced Endoscopic Response at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders40.050.068.830.0100———
Non-responders12.5011.817.4020.011.125.0
Clinical responders28.128.644.836.816.700100
Clinical non-responders15.009.50025.020.00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.691 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -30.8 to 50.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.086 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): 28.8 · 95% CI -2.5 to 60.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.702 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -45.6 to 25.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.557 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.5 · 95% CI -24.0 to -1.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.7 · 95% CI -16.5 to 15.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.707 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.9 · 95% CI -14.4 to 24.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.4 · 95% CI -27.9 to 28.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.175 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -7.2 to 40.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.517 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.7 · 95% CI -18.0 to 35.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.5 · 95% CI -25.5 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Endoscopic Improvement at Week 52

Endoscopic Improvement: SES-CD reduction from Induction Baseline \> 50% or endoscopic remission. Endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Endoscopic Improvement at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders50.050.068.830.0100———
Non-responders12.510.011.817.4020.011.125.0
Clinical responders34.435.744.836.816.700100
Clinical non-responders15.009.50025.020.00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -41.0 to 41.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.257 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.8 · 95% CI -12.8 to 50.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.440 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -55.9 to 15.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.5 · 95% CI -24.3 to 19.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.7 · 95% CI -16.5 to 15.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.440 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -55.9 to 15.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.3 · 95% CI -28.7 to 31.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.404 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.5 · 95% CI -14.0 to 34.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.859 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.5 · 95% CI -24.8 to 29.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.5 · 95% CI -25.5 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Endoscopic Healing at Week 52

Endoscopic healing was defined as SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore \>= 1 at Induction Baseline. SES-CD subscores assess the following: presence and size of ulcers in 5 visualized bowel segments; extent of ulcerated surface in 5 visualized bowel segments; extent of affected surface in 5 visualized bowel segments; presence and type of narrowings in 5 visualized bowel segments. Subscores range from 0 to 15, and are summed for a total SES-CD score ranging from 0 to 56; higher scores indicate greater severity of mucosal inflammation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Endoscopic Healing at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders15.025.050.000———
Non-responders9.410.08.88.7020.000
Clinical responders9.421.431.010.50000
Clinical non-responders15.009.50025.000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.606 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -23.8 to 43.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.034 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significant at the 0.5 level.) · Risk difference (rd): 35.0 · 95% CI 5.9 to 64.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.532 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.6 · 95% CI -20.5 to 21.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.6 · 95% CI -14.4 to 13.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.7 · 95% CI -16.0 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.350 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.1 · 95% CI -11.7 to 35.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.034 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significant at the 0.5 level.) · Risk difference (rd): 21.7 · 95% CI 2.0 to 41.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.2 · 95% CI -15.9 to 18.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.5 · 95% CI -25.5 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Clinical Response Over Time During Extension Phase

Clinical response was defined as average daily stool frequency at least 30% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 30% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Response Over Time During Extension Phase
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2085.010010080.0100———
Responders, Week 2885.075.081.360.00———
Responders, Week 3675.010075.050.0100———
Responders, Week 4450.087.581.340.00———
Responders, Week 5255.087.568.850.0100———
Non-responders, Week 2043.860.041.239.175.020.033.350.0
Non-responders, Week 2840.660.029.426.150.020.022.250.0
Non-responders, Week 3628.140.026.517.450.020.033.325.0
Non-responders, Week 4425.030.026.521.737.540.033.350.0
Non-responders, Week 5221.930.026.513.037.540.033.350.0
Clinical responders, Week 2078.110093.178.910010025.0100
Clinical responders, Week 2878.178.669.057.966.710025.0100
Clinical responders, Week 3665.678.665.547.483.310025.0100
Clinical responders, Week 4450.071.472.442.150.010025.0100
Clinical responders, Week 5250.071.462.142.166.710025.0100
Non-clinical responders, Week 2030.0014.314.333.3040.033.3
Non-clinical responders, Week 2825.025.014.37.10020.033.3
Non-clinical responders, Week 3615.025.09.500040.00
Non-clinical responders, Week 4410.004.87.1025.040.033.3
Non-clinical responders, Week 5210.009.50025.040.033.3
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.536 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.0 · 95% CI -0.6 to 30.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.238 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.0 · 95% CI -0.6 to 30.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -34.3 to 24.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.606 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -43.8 to 23.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.8 · 95% CI -28.5 to 21.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.181 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -59.2 to 9.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.281 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI 6.0 to 44.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -28.5 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.231 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -61.3 to 11.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.099 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significance at the 0.1 level.) · Risk difference (rd): 37.5 · 95% CI 5.8 to 69.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.052 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significance at the 0.1 level.) · Risk difference (rd): 31.3 · 95% CI 2.2 to 60.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.709 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -47.4 to 27.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.194 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 32.5 · 95% CI 0.9 to 64.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.400 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.8 · 95% CI -17.7 to 45.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -42.9 to 32.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.477 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.3 · 95% CI -18.6 to 51.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.833 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.6 · 95% CI -26.4 to 21.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.732 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.6 · 95% CI -30.9 to 21.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.468 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 19.4 · 95% CI -15.4 to 54.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.339 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.2 · 95% CI -34.1 to 11.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.263 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.5 · 95% CI -39.3 to 10.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.697 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.9 · 95% CI -22.3 to 46.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.880 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -23.2 to 19.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.355 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -32.7 to 11.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -27.1 to 37.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.891 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.5 · 95% CI -19.6 to 22.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.779 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.3 · 95% CI -25.8 to 19.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.678 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.1 · 95% CI -23.7 to 39.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.6 · 95% CI -16.0 to 25.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.494 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.8 · 95% CI -28.7 to 11.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.083 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significance at the 0.1 level.) · Risk difference (rd): 21.9 · 95% CI 7.6 to 36.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.151 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.0 · 95% CI -2.1 to 32.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.8 · 95% CI -22.4 to 24.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.4 · 95% CI -25.4 to 26.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.417 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -9.2 · 95% CI -31.3 to 12.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.125 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.2 · 95% CI -46.7 to 6.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.497 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.9 · 95% CI -14.1 to 40.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.993 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.1 · 95% CI -24.0 to 23.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.200 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -18.3 · 95% CI -46.1 to 9.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.177 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.4 · 95% CI -7.9 to 50.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.074 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified significance at the 0.1 level.) · Risk difference (rd): 22.4 · 95% CI -1.4 to 46.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.585 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.9 · 95% CI -36.1 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.177 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.4 · 95% CI -7.9 to 50.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.343 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.1 · 95% CI -12.7 to 36.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.585 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.9 · 95% CI -36.1 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.539 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -30.0 · 95% CI -50.1 to -9.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.277 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.7 · 95% CI -40.8 to 9.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.422 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.7 · 95% CI -42.9 to 11.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -46.5 to 46.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.454 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -34.9 to 13.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.364 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.9 · 95% CI -41.1 to 5.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.544 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -35.2 to 55.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.5 · 95% CI -25.5 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.606 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.2 · 95% CI -21.2 to 10.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.9 · 95% CI -21.7 to 16.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.5 · 95% CI -18.7 to 17.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.501 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase

Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline OR average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2070.087.510070.0100———
Responders, Week 2880.075.081.360.00———
Responders, Week 3675.010075.040.0100———
Responders, Week 4450.062.575.040.00———
Responders, Week 5250.087.568.850.0100———
Non-responders, Week 2034.450.038.226.150.020.033.325.0
Non-responders, Week 2837.560.029.421.770.020.022.250.0
Non-responders, Week 3628.140.026.517.450.020.033.325.0
Non-responders, Week 4421.930.023.521.737.520.033.350.0
Non-responders, Week 5221.930.026.513.037.540.033.350.0
Clinical responders, Week 2062.585.793.163.283.310025.0100
Clinical responders, Week 2871.978.669.057.966.710025.0100
Clinical responders, Week 3665.678.665.542.183.310025.0100
Clinical responders, Week 4450.057.165.542.150.010025.0100
Clinical responders, Week 5246.971.462.142.166.710025.0100
Clinical non-responders, Week 2025.009.57.10040.00
Clinical non-responders, Week 2825.025.014.300020.033.3
Clinical non-responders, Week 3615.025.09.500040.00
Clinical non-responders, Week 445.004.87.10040.033.3
Clinical non-responders, Week 5210.009.50025.040.033.3
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.633 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 17.5 · 95% CI -13.0 to 48.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.0024 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 30.0 · 95% CI 9.9 to 50.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -34.8 to 34.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -39.8 to 29.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.3 · 95% CI -24.7 to 27.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.384 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -55.1 to 15.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.281 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI 6.0 to 44.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -28.5 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.108 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -35.0 · 95% CI -70.8 to 0.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -27.6 to 52.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.126 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -5.5 to 55.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.709 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -47.4 to 27.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.099 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 37.5 · 95% CI 5.8 to 69.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.257 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.8 · 95% CI -12.8 to 50.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -38.0 to 38.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.465 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.6 · 95% CI -19.5 to 50.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.745 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.9 · 95% CI -19.3 to 27.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.512 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.3 · 95% CI -32.6 to 16.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.281 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 22.5 · 95% CI -12.2 to 57.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.486 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.1 · 95% CI -30.8 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.212 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.8 · 95% CI -39.5 to 8.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.697 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.9 · 95% CI -22.3 to 46.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.880 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -23.2 to 19.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.355 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -32.7 to 11.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.678 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.1 · 95% CI -23.7 to 39.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.873 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.7 · 95% CI -18.6 to 21.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.990 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.1 · 95% CI -22.3 to 22.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.678 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.1 · 95% CI -23.7 to 39.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.6 · 95% CI -16.0 to 25.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.494 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.8 · 95% CI -28.7 to 11.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.169 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.2 · 95% CI -1.6 to 48.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.005 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 30.6 · 95% CI 11.5 to 49.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.963 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.7 · 95% CI -26.8 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.729 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.7 · 95% CI -19.8 to 33.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.804 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.9 · 95% CI -25.8 to 20.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.306 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.0 · 95% CI -41.1 to 13.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.497 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.9 · 95% CI -14.1 to 40.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.993 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.1 · 95% CI -24.0 to 23.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.101 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -23.5 · 95% CI -51.2 to 4.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.655 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.1 · 95% CI -24.0 to 38.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.221 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.5 · 95% CI -9.0 to 40.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.585 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.9 · 95% CI -36.1 to 20.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.124 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 24.6 · 95% CI -4.8 to 53.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.234 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.2 · 95% CI -9.5 to 39.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.741 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.8 · 95% CI -32.9 to 23.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.544 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -44.0 to -6.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.238 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.5 · 95% CI -38.2 to 7.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.364 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.9 · 95% CI -41.1 to 5.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -46.5 to 46.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.454 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -34.9 to 13.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.063 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -44.0 to -6.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.544 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -35.2 to 55.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.663 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.5 · 95% CI -25.5 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -14.6 to 4.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.2 · 95% CI -13.4 to 13.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.1 · 95% CI -14.4 to 18.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.5 · 95% CI -18.7 to 17.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.501 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase Among Participants In Enhanced Clinical Response At Week 16

Enhanced clinical response was defined as average daily stool frequency at least 60% reduction from Induction Baseline and average daily abdominal pain not worse than Induction Baseline or average daily abdominal pain at least 35% reduction from Induction Baseline and average daily stool frequency not worse than Induction Baseline or modified clinical remission (average daily stool frequency ≤ 2.8 and not worse than Induction baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction baseline). The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Enhanced Clinical Response Over Time During Extension Phase Among Participants In Enhanced Clinical Response At Week 16
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2070.010010066.7————
Responders, Week 2880.071.481.355.6————
Responders, Week 3675.010075.033.3————
Responders, Week 4450.071.475.033.3————
Responders, Week 5250.085.768.844.4————
Non-responders, Week 2050.083.383.357.110010050.0100
Non-responders, Week 2870.083.358.357.110010050.0100
Non-responders, Week 3650.050.058.357.110010050.0100
Non-responders, Week 4450.050.058.357.175.010050.0100
Non-responders, Week 5240.050.058.342.975.010050.0100
Clinical Responders, Week 2063.392.392.966.710010050.0100
Clinical Responders, Week 2876.776.971.460.010010050.0100
Clinical Responders, Week 3666.776.967.946.710010050.0100
Clinical Responders, Week 4450.061.567.946.775.010050.0100
Clinical Responders, Week 5246.769.264.346.775.010050.0100
Clinical Non-responders, Week 20———0————
Clinical Non-responders, Week 28———0————
Clinical Non-responders, Week 36———0————
Clinical Non-responders, Week 44———0————
Clinical Non-responders, Week 52———0————
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.155 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 30.0 · 95% CI 9.9 to 50.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.024 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 30.0 · 95% CI 9.9 to 50.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.3 · 95% CI -40.1 to 33.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.633 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.6 · 95% CI -46.4 to 29.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.3 · 95% CI -24.7 to 27.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.209 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -24.4 · 95% CI -61.3 to 12.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.283 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI 6.0 to 44.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -28.5 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.048 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -41.7 · 95% CI -77.8 to -5.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.408 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 21.4 · 95% CI -18.6 to 61.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.126 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -5.5 to 55.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.454 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -54.5 to 21.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.183 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 35.7 · 95% CI 1.8 to 69.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.257 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.8 · 95% CI -12.8 to 50.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANOVA · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.6 · 95% CI -44.7 to 33.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.307 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -9.7 to 76.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.172 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -4.1 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.1 · 95% CI -40.9 to 55.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -27.8 to 54.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.675 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.7 · 95% CI -51.5 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.644 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.9 · 95% CI -59.2 to 33.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -50.6 to 50.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -33.4 to 50.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.1 · 95% CI -40.9 to 55.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -50.6 to 50.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -33.4 to 50.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 7.1 · 95% CI -40.9 to 55.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -40.2 to 60.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.392 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.3 · 95% CI -22.9 to 59.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 2.9 · 95% CI -44.7 to 50.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.070 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 29.0 · 95% CI 6.5 to 51.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.007 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 29.5 · 95% CI 9.8 to 49.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.826 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 3.3 · 95% CI -26.1 to 32.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.3 · 95% CI -27.2 to 27.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.649 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.2 · 95% CI -27.8 to 17.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.304 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -45.7 to 12.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.720 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.3 · 95% CI -18.2 to 38.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.923 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 1.2 · 95% CI -23.0 to 25.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.197 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -50.4 to 10.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.486 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.5 · 95% CI -20.4 to 43.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.168 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 17.9 · 95% CI -7.0 to 42.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.833 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.3 · 95% CI -34.3 to 27.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.173 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 22.6 · 95% CI -8.2 to 53.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.178 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 17.6 · 95% CI -7.6 to 42.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -30.9 to 30.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase Among Participants With an Average Daily Stool Frequency ≥ 2.5 and Average Daily Abdominal Pain ≥ 2.0 at Induction Baseline

Clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Remission Over Time During Extension Phase Among Participants With an Average Daily Stool Frequency ≥ 2.5 and Average Daily Abdominal Pain ≥ 2.0 at Induction Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in Induction
Responders, Week 2044.416.737.520.0
Responders, Week 2855.616.750.040.0
Responders, Week 3644.416.750.020.0
Responders, Week 4444.4050.040.0
Responders, Week 5233.333.350.020.0
Non-responders, Week 2021.440.06.711.1
Non-responders, Week 2821.440.06.722.2
Non-responders, Week 3621.420.0022.2
Non-responders, Week 4414.320.06.711.1
Non-responders, Week 527.120.013.322.2
Clinical responders, Week 2041.230.026.722.2
Clinical responders, Week 2847.130.033.344.4
Clinical responders, Week 3641.220.026.733.3
Clinical responders, Week 4435.310.033.333.3
Clinical responders, Week 5223.530.040.033.3
Clinical non-responders, Week 200000
Clinical non-responders, Week 280000
Clinical non-responders, Week 360000
Clinical non-responders, Week 440000
Clinical non-responders, Week 520000
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.580 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -27.8 · 95% CI -71.9 to 16.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.9 · 95% CI -53.6 to 39.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.580 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -24.4 · 95% CI -72.2 to 23.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.287 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -38.9 · 95% CI -83.0 to 5.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.6 · 95% CI -53.0 to 41.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.6 · 95% CI -69.4 to 38.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.580 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -27.8 · 95% CI -71.9 to 16.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.6 · 95% CI -41.9 to 53.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.580 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -24.4 · 95% CI -72.2 to 23.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.103 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -44.4 · 95% CI -76.9 to -12.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.6 · 95% CI -41.9 to 53.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.4 · 95% CI -58.3 to 49.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -48.7 to 48.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.637 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -29.7 to 63.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -60.0 to 33.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.570 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.6 · 95% CI -29.4 to 66.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.330 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.8 · 95% CI -39.7 to 10.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -10.3 · 95% CI -40.0 to 19.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.570 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 18.6 · 95% CI -29.4 to 66.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.330 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.8 · 95% CI -39.7 to 10.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.8 · 95% CI -33.8 to 35.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.4 · 95% CI -42.6 to 39.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.100 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -21.4 · 95% CI -42.9 to 0.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.8 · 95% CI -33.8 to 35.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.7 · 95% CI -33.8 to 45.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.598 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.6 · 95% CI -29.9 to 14.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -3.2 · 95% CI -30.7 to 24.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.468 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.9 · 95% CI -24.7 to 50.4
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.2 · 95% CI -15.7 to 28.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.538 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 15.1 · 95% CI -15.2 to 45.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.692 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.2 · 95% CI -48.0 to 25.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.388 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.5 · 95% CI -46.9 to 17.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.418 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -19.0 · 95% CI -54.8 to 16.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.448 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.1 · 95% CI -54.1 to 20.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.430 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.7 · 95% CI -47.4 to 19.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.6 · 95% CI -42.8 to 37.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.406 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -21.2 · 95% CI -55.3 to 12.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.388 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.5 · 95% CI -46.9 to 17.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -7.8 · 95% CI -46.5 to 30.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.204 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.3 · 95% CI -54.7 to 4.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.907 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.0 · 95% CI -34.9 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.0 · 95% CI -40.2 to 36.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.5 · 95% CI -28.4 to 41.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.450 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.5 · 95% CI -15.5 to 48.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.661 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 9.8 · 95% CI -27.0 to 46.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 Over Time

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve CDAI < 150 Over Time
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2050.050.075.00————
Responders, Week 2850.050.050.020.0————
Responders, Week 3650.010050.00————
Responders, Week 4437.550.050.020.0————
Responders, Week 5250.010062.50————
Non-responders, Week 2013.340.08.300—00
Non-responders, Week 286.740.016.711.10—00
Non-responders, Week 3613.340.08.311.10—00
Non-responders, Week 4426.740.025.011.10—00
Non-responders, Week 5220.040.025.011.10—00
Clinical responders, Week 2040.050.050.000—0—
Clinical responders, Week 2833.350.042.925.00—0—
Clinical responders, Week 3640.066.735.712.50—0—
Clinical responders, Week 4440.050.050.025.00—0—
Clinical responders, Week 5246.766.757.112.50—0—
Clinical non-responders, Week 2000000—00
Clinical non-responders, Week 2800000—00
Clinical non-responders, Week 3600000—00
Clinical non-responders, Week 4412.50000—00
Clinical non-responders, Week 5200000—00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -77.5 to 77.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.608 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -20.8 to 70.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.105 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -84.6 to -15.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -77.5 to 77.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -49.0 to 49.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANOVA · p = 0.565 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -30.0 · 95% CI -79.3 to 19.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.467 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 50.0 · 95% CI 15.4 to 84.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -49.0 to 49.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.105 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -84.6 to -15.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -64.5 to 89.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -35.7 to 60.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.5 · 95% CI -66.0 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.467 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 50.0 · 95% CI 15.4 to 84.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -35.7 to 60.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.105 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -84.6 to -15.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.249 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.7 · 95% CI -19.6 to 72.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -28.2 to 18.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.511 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -30.5 to 3.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.140 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -11.4 to 78.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.569 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -14.6 to 34.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -19.7 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.249 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.7 · 95% CI -19.6 to 72.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -28.2 to 18.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.2 · 95% CI -29.0 to 24.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.613 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -35.1 to 61.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -34.8 to 31.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.615 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.6 · 95% CI -45.9 to 14.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.560 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -27.5 to 67.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -26.8 to 36.8
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.9 · 95% CI -37.7 to 19.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -37.1 to 57.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.588 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -26.1 to 46.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.058 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): -40.0 · 95% CI -64.8 to -15.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.631 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -29.9 to 63.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.597 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 9.5 · 95% CI -25.7 to 44.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.3 · 95% CI -46.7 to 30.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.361 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.7 · 95% CI -18.5 to 71.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.812 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.3 · 95% CI -39.6 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.345 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -27.5 · 95% CI -61.3 to 6.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -37.1 to 57.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.588 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -26.1 to 46.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.657 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -53.9 to 23.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.635 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -25.4 to 65.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.573 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.5 · 95% CI -25.7 to 46.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.176 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -34.2 · 95% CI -68.3 to -0.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.5 · 95% CI -35.4 to 10.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.5 · 95% CI -35.4 to 10.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -12.5 · 95% CI -35.4 to 10.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Remission At Week 52

Steroid-free remission at Week 52 was defined as both endoscopic remission at Week 52 and clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2 point reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Clinical remission: Average daily stool frequency ≤ 1.5 and not worse than baseline AND average daily abdominal pain ≤ 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). See SES-CD description details in the first primary endpoint description of this record.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Remission At Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders25.0037.50————
Non-responders00011.10—00
Clinical Responders13.3021.412.50—0—
Clinical non-responders00000—00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -32.5 to 57.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.487 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.375 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 11.1 · 95% CI -9.4 to 31.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -30.5 to 3.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.651 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 8.1 · 95% CI -19.4 to 35.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -0.8 · 95% CI -29.5 to 27.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission Over Time

Steroid-free clinical remission was defined as average daily stool frequency \<= 1.5 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Clinical Remission Over Time
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2050.050.050.00————
Responders, Week 2837.550.050.020.0————
Responders, Week 3637.510062.50————
Responders, Week 4437.5062.520.0————
Responders, Week 5225.010062.50————
Non-responders, Week 2013.340.0000—00
Non-responders, Week 286.740.016.711.10—00
Non-responders, Week 366.720.0011.10—00
Non-responders, Week 4420.040.0011.10—00
Non-responders, Week 5213.320.08.311.10—00
Clinical responders, Week 2040.050.028.600—0—
Clinical responders, Week 2826.750.042.925.00—0—
Clinical responders, Week 3626.750.035.712.50—0—
Clinical responders, Week 4440.033.335.725.00—0—
Clinical responders, Week 5226.750.042.912.50—0—
Clinical non-responders, Week 2000000—00
Clinical non-responders, Week 2800000—00
Clinical non-responders, Week 3600000—00
Clinical non-responders, Week 4400000—00
Clinical non-responders, Week 5200000—00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -77.5 to 77.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -49.0 to 49.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.105 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -84.6 to -15.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -64.5 to 89.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -35.7 to 60.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.5 · 95% CI -66.0 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.444 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 62.5 · 95% CI 29.0 to 96.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.619 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -22.4 to 72.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.231 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -37.5 · 95% CI -71.0 to -4.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -37.5 · 95% CI -71.0 to -4.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.619 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -22.4 to 72.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -17.5 · 95% CI -66.0 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.133 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 75.0 · 95% CI 45.0 to 100.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.315 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 37.5 · 95% CI -7.5 to 82.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.487 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.249 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 26.7 · 95% CI -19.6 to 72.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.487 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -30.5 to 3.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.511 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -30.5 to 3.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.140 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -11.4 to 78.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.569 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -14.6 to 34.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -19.7 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.447 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 13.3 · 95% CI -23.9 to 50.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.7 · 95% CI -19.3 to 6.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -19.7 to 28.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.560 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -27.5 to 67.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.231 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -40.2 to 0.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -8.9 · 95% CI -37.7 to 19.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 6.7 · 95% CI -32.4 to 45.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -28.2 to 18.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -2.2 · 95% CI -29.0 to 24.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -37.1 to 57.1Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.700 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -11.4 · 95% CI -45.7 to 22.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.058 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5). Prespecified statistical significance at the 0.1 level.) · Risk difference (rd): -40.0 · 95% CI -64.8 to -15.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.354 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -22.5 to 69.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.450 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.2 · 95% CI -18.1 to 50.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -39.1 to 35.8Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.354 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -22.5 to 69.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.700 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 9.0 · 95% CI -24.6 to 42.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.621 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.2 · 95% CI -46.2 to 17.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -6.7 · 95% CI -51.8 to 38.5Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.812 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -4.3 · 95% CI -39.6 to 31.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.657 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -53.9 to 23.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.354 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -22.5 to 69.2Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.450 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.2 · 95% CI -18.1 to 50.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.621 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -14.2 · 95% CI -46.2 to 17.9Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Taking Corticosteroids at Induction Baseline and With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Modified Clinical Remission Over Time

Steroid-free modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than Induction Baseline AND average daily abdominal pain \<= 1.0 and not worse than Induction Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Induction Baseline and With Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Modified Clinical Remission Over Time
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2033.350.062.520.0————
Responders, Week 2850.050.062.520.0————
Responders, Week 3650.010062.50————
Responders, Week 4433.350.062.520.0————
Responders, Week 5233.310062.50————
Non-responders, Week 208.340.08.300—00
Non-responders, Week 2816.740.016.712.50—00
Non-responders, Week 368.320.08.312.50—00
Non-responders, Week 4416.740.0012.50—00
Non-responders, Week 528.320.016.712.50—00
Clinical responders, Week 2025.050.042.914.30—0—
Clinical responders, Week 2841.750.050.028.60—0—
Clinical responders, Week 3633.350.042.914.30—0—
Clinical responders, Week 4433.350.035.728.60—0—
Clinical responders, Week 5225.050.050.014.30—0—
Clinical non-responders, Week 2000000—00
Clinical non-responders, Week 2800000—00
Clinical non-responders, Week 3600000—00
Clinical non-responders, Week 4400000—00
Clinical non-responders, Week 5200000—00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20%of the cells have expected cell count \<5).) · Risk difference (rd): 16.7 · 95% CI -62.2 to 95.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.592 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 29.2 · 95% CI -21.3 to 79.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -64.8 to 38.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -80.0 to 80.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -39.7 to 64.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.545 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -30.0 · 95% CI -83.2 to 23.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.464 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 50.0 · 95% CI 10.0 to 90.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 12.5 · 95% CI -39.7 to 64.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.182 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -90.0 to -10.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -62.2 to 95.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.592 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 29.2 · 95% CI -21.3 to 79.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -13.3 · 95% CI -64.8 to 38.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.429 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 66.7 · 95% CI 28.9 to 100.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.592 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 29.2 · 95% CI -21.3 to 79.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.455 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -71.1 to 4.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.191 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 31.7 · 95% CI -14.0 to 77.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 · Risk difference (rd): 0.0 · 95% CI -22.1 to 22.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -8.3 · 95% CI -24.0 to 7.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.538 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -24.5 to 71.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -29.8 to 29.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -4.2 · 95% CI -35.3 to 27.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.515 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.7 · 95% CI -26.7 to 50.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -22.1 to 22.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.2 · 95% CI -23.6 to 31.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.538 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 23.3 · 95% CI -24.5 to 71.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.478 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -16.7 · 95% CI -37.8 to 4.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -4.2 · 95% CI -35.3 to 27.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.515 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.7 · 95% CI -26.7 to 50.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -17.9 to 34.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.2 · 95% CI -23.6 to 31.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.344 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -21.9 to 71.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.429 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 17.9 · 95% CI -17.8 to 53.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 · Risk difference (rd): -10.7 · 95% CI -46.4 to 25.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -40.4 to 57.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.671 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -29.9 to 46.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.656 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -13.1 · 95% CI -56.7 to 30.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.627 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -31.4 to 64.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.701 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 9.5 · 95% CI -27.7 to 46.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.603 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -19.0 · 95% CI -56.2 to 18.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.627 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -31.4 to 64.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 2.4 · 95% CI -34.2 to 39.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -4.8 · 95% CI -47.6 to 38.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.344 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -21.9 to 71.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.248 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -10.9 to 60.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -46.4 to 25.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
SecondaryPercentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 52

Steroid-free endoscopic remission was defined as SES-CD \<= 4 and at least 2 points reduction versus Induction Baseline and no subscore \> 1 in any individual variable. Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Taking Corticosteroids at Induction Baseline Who Discontinued Corticosteroid Use and Achieve Endoscopic Remission at Week 52
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders25.0050.00————
Non-responders020.08.311.10—00
Clinical responders13.316.735.712.50—0—
Clinical non-responders00000—00
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.608 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI -20.8 to 70.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.487 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.250 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -15.1 to 55.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.444 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 8.3 · 95% CI -7.3 to 24.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.375 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.1 · 95% CI -9.4 to 31.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 3.3 · 95% CI -31.1 to 37.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.215 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 22.4 · 95% CI -8.0 to 52.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.8 · 95% CI -29.5 to 27.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
SecondaryPercentage Of Participants Who Achieve CDAI < 150 Over Time During Extension Phase

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A score below 150 indicates remission.

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage Of Participants Who Achieve CDAI < 150 Over Time During Extension Phase
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2065.050.075.050.00———
Responders, Week 2875.025.062.560.00———
Responders, Week 3670.075.062.530.00———
Responders, Week 4445.037.562.540.00———
Responders, Week 5255.050.068.840.00———
Non-responders, Week 2028.150.017.68.775.020.011.150.0
Non-responders, Week 2815.640.017.613.037.520.022.250.0
Non-responders, Week 3615.630.014.713.037.520.033.350.0
Non-responders, Week 4418.830.017.68.725.020.033.325.0
Non-responders, Week 529.430.020.613.025.040.033.350.0
Clinical responders, Week 2059.464.351.736.883.31000100
Clinical responders, Week 2856.342.948.347.450.010025.0100
Clinical responders, Week 3659.464.344.831.650.010025.0100
Clinical responders, Week 4440.642.955.231.633.310025.0100
Clinical responders, Week 5243.850.055.236.833.310025.0100
Clinical non- responders, Week 2015.0014.3033.3020.033.3
Clinical non- responders, Week 2810.009.500020.033.3
Clinical non- responders, Week 36009.500040.033.3
Clinical non- responders, Week 4410.00000040.00
Clinical non- responders, Week 52009.50025.040.033.3
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.671 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -55.5 to 25.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.718 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -19.8 to 39.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.461 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -52.4 to 22.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.030 (Statistically significant at 0.05 level. P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -85.5 to -14.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.483 · Risk difference (rd): -12.5 · 95% CI -42.9 to 17.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.431 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -50.8 to 20.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -31.1 to 41.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.635 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -7.5 · 95% CI -38.6 to 23.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.056 (Statistically significant at 0.1 level. P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -40.0 · 95% CI -74.8 to -5.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -7.5 · 95% CI -47.5 to 32.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.296 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 17.5 · 95% CI -14.7 to 49.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -42.4 to 32.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -45.9 to 35.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.400 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 13.8 · 95% CI -17.7 to 45.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.439 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -52.4 to 22.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.259 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 21.9 · 95% CI -12.8 to 56.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.310 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.5 · 95% CI -30.6 to 9.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.097 (Statistically significant at 0.1 level. P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -19.4 · 95% CI -38.8 to -0.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.181 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 24.4 · 95% CI -8.5 to 57.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.826 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 2.0 · 95% CI -15.9 to 20.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -2.6 · 95% CI -21.2 to 16.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.369 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 14.4 · 95% CI -16.7 to 45.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.9 · 95% CI -18.2 to 16.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -2.6 · 95% CI -21.2 to 16.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.660 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.3 · 95% CI -20.2 to 42.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.908 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -1.1 · 95% CI -19.7 to 17.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.446 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.1 · 95% CI -27.8 to 7.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.135 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.6 · 95% CI -9.5 to 50.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.306 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.2 · 95% CI -5.7 to 28.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.686 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 3.7 · 95% CI -13.4 to 20.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.754 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.9 · 95% CI -25.4 to 35.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.548 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -7.7 · 95% CI -32.6 to 17.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.120 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -22.5 · 95% CI -50.1 to 5.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.403 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -13.4 · 95% CI -44.5 to 17.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.533 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -8.0 · 95% CI -33.0 to 17.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.539 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -8.9 · 95% CI -37.2 to 19.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.754 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.9 · 95% CI -25.4 to 35.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.256 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -14.5 · 95% CI -39.4 to 10.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.055 (Statistically significant at 0.1 level.) · Risk difference (rd): -27.8 · 95% CI -54.7 to -0.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.887 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 2.2 · 95% CI -28.8 to 33.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.256 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 14.5 · 95% CI -10.3 to 39.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.518 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -9.0 · 95% CI -36.0 to 17.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.695 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 6.3 · 95% CI -25.1 to 37.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.373 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 11.4 · 95% CI -13.5 to 36.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.628 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -6.9 · 95% CI -34.6 to 20.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.7 · 95% CI -22.4 to 20.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.251 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -30.6 to 0.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.5 · 95% CI -18.7 to 17.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.501 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.488 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 9.5 · 95% CI -3.0 to 22.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.232 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.501 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.488 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 9.5 · 95% CI -3.0 to 22.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
SecondaryPercentage of Participants With Decrease in CDAI ≥ 70 Points From Induction Baseline Over Time During Extension Phase

CDAI is used to quantify the signs and symptoms of subjects with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. A 70-point decrease in the CDAI index refers to improvement in the disease activity from Baseline.

Time frame:
Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Decrease in CDAI ≥ 70 Points From Induction Baseline Over Time During Extension Phase
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 2080.010093.860.0100———
Responders, Week 2885.062.568.860.00———
Responders, Week 3675.010075.050.0100———
Responders, Week 4460.087.581.340.0100———
Responders, Week 5255.075.075.040.0100———
Non-responders, Week 2046.970.047.134.875.020.022.250.0
Non-responders, Week 2834.460.029.430.450.020.033.350.0
Non-responders, Week 3628.150.026.517.450.020.033.350.0
Non-responders, Week 4425.030.029.426.137.540.033.325.0
Non-responders, Week 5212.540.026.517.437.540.033.350.0
Clinical responders, Week 2075.010089.763.21001000100
Clinical responders, Week 2875.071.458.657.966.710025.0100
Clinical responders, Week 3665.685.762.142.183.310025.0100
Clinical responders, Week 4456.371.472.442.166.710025.0100
Clinical responders, Week 5246.971.462.136.866.710025.0100
Clinical non-responders, Week 2035.025.023.814.333.3040.033.3
Clinical non-responders, Week 2820.025.019.014.30040.033.3
Clinical non-responders, Week 3615.025.014.37.10040.033.3
Clinical non-responders, Week 4410.009.514.3025.040.00
Clinical non-responders, Week 520014.37.1025.040.033.3
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.295 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI 2.5 to 37.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.355 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 13.8 · 95% CI -7.4 to 34.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.384 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -55.1 to 15.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.311 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -22.5 · 95% CI -59.5 to 14.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.422 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -16.3 · 95% CI -43.8 to 11.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.181 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -59.2 to 9.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.281 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI 6.0 to 44.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 0.0 · 95% CI -28.5 to 28.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.231 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -61.3 to 11.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.214 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 27.5 · 95% CI -3.9 to 58.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.277 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 21.3 · 95% CI -7.5 to 50.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.442 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -20.0 · 95% CI -57.2 to 17.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.419 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -17.1 to 57.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.214 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.0 · 95% CI -10.4 to 50.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.439 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -15.0 · 95% CI -52.4 to 22.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.284 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 23.1 · 95% CI -10.1 to 56.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.988 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 0.2 · 95% CI -23.9 to 24.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.370 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -12.1 · 95% CI -38.1 to 13.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.268 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.6 · 95% CI -8.9 to 60.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.665 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -5.0 · 95% CI -27.4 to 17.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.759 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -3.9 · 95% CI -28.9 to 21.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.259 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 21.9 · 95% CI -12.8 to 56.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.880 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -1.7 · 95% CI -23.2 to 19.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.355 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.7 · 95% CI -32.7 to 11.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -27.1 to 37.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.688 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.4 · 95% CI -17.0 to 25.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.927 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 1.1 · 95% CI -22.3 to 24.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.075 (Statistically significant at 0.1 level. P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 27.5 · 95% CI -5.0 to 60.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.154 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 14.0 · 95% CI -4.8 to 32.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.707 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.9 · 95% CI -14.4 to 24.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.085 (Statistically significant at 0.1 level. P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 25.0 · 95% CI 10.0 to 40.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.137 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 14.7 · 95% CI -4.0 to 33.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.370 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -11.8 · 95% CI -38.2 to 14.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -3.6 · 95% CI -31.6 to 24.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.174 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -16.4 · 95% CI -39.8 to 7.0Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.203 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -17.1 · 95% CI -43.9 to 9.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.286 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 20.1 · 95% CI -4.5 to 44.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.773 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -3.6 · 95% CI -27.7 to 20.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.101 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -23.5 · 95% CI -51.2 to 4.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.332 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 15.2 · 95% CI -14.1 to 44.4Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.189 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 16.2 · 95% CI -7.5 to 39.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.329 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -14.1 · 95% CI -42.2 to 13.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.124 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 24.6 · 95% CI -4.8 to 53.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.234 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 15.2 · 95% CI -9.5 to 39.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.484 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -37.8 to 17.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -57.3 to 37.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.431 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -11.2 · 95% CI -38.9 to 16.5Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.250 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -20.7 · 95% CI -48.5 to 7.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 5.0 · 95% CI -40.9 to 50.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -1.0 · 95% CI -25.2 to 23.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -5.7 · 95% CI -31.1 to 19.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.544 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 10.0 · 95% CI -35.2 to 55.2Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.7 · 95% CI -22.4 to 20.9Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.627 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -7.9 · 95% CI -28.5 to 12.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -10.0 · 95% CI -23.1 to 3.1Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): -0.5 · 95% CI -18.7 to 17.7Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 4.3 · 95% CI -18.3 to 26.8Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.232 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 14.3 · 95% CI -0.7 to 29.3Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.412 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells have expected cell count \< 5).) · Risk difference (rd): 7.1 · 95% CI -6.3 to 20.6Risk difference = upadacitinib higher dose - upadacitinib lower dose. 95% confidence intervals for risk difference were calculated based on normal approximation using proc freq.
SecondaryChange From Induction Baseline in Fecal Calprotectin Level Over Time During Extension Phase
Time frame:
Baseline, Week 28, Week 52
Reported as:
Mean · mcg/g
Change From Induction Baseline in Fecal Calprotectin Level Over Time During Extension Phase
mcg/gUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 28-153.4 ± 2722.96-532.0 ± 519.42-2878.6 ± 2584.43-3563.7 ± 4747.26-194.0 ± NA———
Responders, Week 52-51.9 ± 2650.98-524.1 ± 521.31-3047.5 ± 2509.27-2371.8 ± 2786.97-44.0 ± NA———
Non-responders, Week 28-150.3 ± 958.76-148.3 ± 1315.46-834.5 ± 3011.51-850.2 ± 1821.34-16.5 ± 304.33-121.0 ± 395.16-326.8 ± 817.71760.5 ± 1075.51
Non-responders, Week 52-87.2 ± 1494.3588.3 ± 1689.67-704.0 ± 2801.08-562.8 ± 1738.58-8.3 ± 344.29-121.0 ± 395.16-434.0 ± 1030.64760.5 ± 1075.51
Clinical responders, Week 28-226.2 ± 2261.16-424.5 ± 1102.22-2794.6 ± 3018.26-2099.3 ± 3083.34-65.0 ± 316.06-694.0 ± NA117.5 ± 166.17—
Clinical responders, Week 521.0 ± 2457.22-239.3 ± 1443.14-2617.4 ± 3232.04-1510.3 ± 2773.90-44.3 ± 350.61-694.0 ± NA117.5 ± 166.17—
Clinical non-responders, Week 283.7 ± 766.69-30.7 ± 32.65606.0 ± 1133.70183.7 ± 443.970.0 ± NA70.0 ± 123.85-771.0 ± 1090.36760.5 ± 1075.51
Clinical non-responders, Week 52-220.2 ± 514.97-30.7 ± 32.65213.3 ± 802.34183.7 ± 443.970.0 ± NA70.0 ± 123.85-985.5 ± 1393.71760.5 ± 1075.51
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.356 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -745.7 · 95% CI -2369.73 to 878.37
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.158 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1119.5 · 95% CI -2698.52 to 459.50
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.322 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1166.0 · 95% CI -3531.30 to 1199.32
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.287 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -828.2 · 95% CI -2387.16 to 730.75
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.088 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1286.1 · 95% CI -2772.59 to 200.43Prespecified statistically significant at 0.1 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.613 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -502.2 · 95% CI -2505.74 to 1501.38
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.609 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 283.4 · 95% CI -823.64 to 1390.49
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.855 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -78.2 · 95% CI -930.47 to 774.16
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.584 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 283.5 · 95% CI -751.66 to 1318.57
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.624 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 356.6 · 95% CI -1095.03 to 1808.19
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.806 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -135.1 · 95% CI -1233.48 to 963.25
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.793 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 186.2 · 95% CI -1229.59 to 1602.06
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.561 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -304.8 · 95% CI -1350.04 to 740.44
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.024 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1119.0 · 95% CI -2083.81 to -154.11Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.156 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -819.3 · 95% CI -1959.79 to 321.21
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.580 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -346.6 · 95% CI -1592.66 to 899.45
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.029 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1275.9 · 95% CI -2415.88 to -135.92Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.431 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -534.9 · 95% CI -1883.23 to 813.50
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.965 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -25.4 · 95% CI -1200.67 to 1149.95
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.123 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 623.6 · 95% CI -183.52 to 1430.64
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.591 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 368.2 · 95% CI -1031.23 to 1767.60
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.642 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 192.2 · 95% CI -648.22 to 1032.68
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.093 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 455.8 · 95% CI -81.37 to 992.95Prespecified statistically significant at 0.1 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.296 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 463.6 · 95% CI -428.99 to 1356.20
SecondaryChange From Induction Baseline in Hs-CRP Over Time During Extension Phase
Time frame:
Baseline, Week 20, Week 28, Week 36, Week 44, Week 52
Reported as:
Mean · mg/L
Change From Induction Baseline in Hs-CRP Over Time During Extension Phase
mg/LUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders, Week 20-9.5 ± 21.77-9.4 ± 11.14-20.8 ± 19.784.1 ± 36.50-3.1 ± NA———
Responders, Week 28-6.0 ± 22.53-3.6 ± 16.12-21.8 ± 17.937.0 ± 35.65-4.2 ± NA———
Responders, Week 36-1.8 ± 25.57-7.2 ± 10.86-22.5 ± 18.015.6 ± 35.87-4.0 ± NA———
Responders, Week 44-5.4 ± 22.95-8.5 ± 12.18-21.5 ± 19.785.8 ± 35.7710.6 ± NA———
Responders, Week 52-4.3 ± 22.68-7.0 ± 12.66-20.4 ± 18.766.2 ± 35.820.4 ± NA———
Non-responders, Week 20-2.2 ± 9.72-1.6 ± 8.24-8.5 ± 25.00-8.0 ± 18.770.3 ± 10.89-1.0 ± 0.97-6.8 ± 8.82-1.5 ± 2.39
Non-responders, Week 28-3.0 ± 9.61-0.2 ± 5.92-6.4 ± 27.03-6.5 ± 20.140.3 ± 9.78-1.1 ± 1.06-5.9 ± 6.583.8 ± 9.55
Non-responders, Week 36-0.7 ± 8.865.2 ± 15.34-7.3 ± 24.870.8 ± 45.983.3 ± 8.880.5 ± 0.41-3.7 ± 7.808.3 ± 12.71
Non-responders, Week 44-1.3 ± 7.8211.1 ± 33.68-4.1 ± 27.930.9 ± 45.883.0 ± 9.51-0.9 ± 0.87-4.1 ± 7.125.5 ± 9.39
Non-responders, Week 52-1.2 ± 8.672.8 ± 17.81-3.4 ± 32.581.3 ± 45.264.7 ± 11.50-0.2 ± 0.42-5.1 ± 8.522.5 ± 9.89
Clinical responders, Week 20-7.1 ± 18.6-6.9 ± 10.80-18.0 ± 29.20-3.0 ± 31.35-3.8 ± 5.59-2.2 ± NA-9.5 ± 12.15-4.4 ± NA
Clinical responders, Week 28-5.4 ± 19.26-2.0 ± 12.93-19.2 ± 30.130.0 ± 32.17-4.0 ± 4.77-2.3 ± NA-6.1 ± 6.32-5.3 ± NA
Clinical responders, Week 36-0.8 ± 20.85-0.5 ± 16.69-18.6 ± 28.629.1 ± 56.330.1 ± 5.930.4 ± NA-3.2 ± 9.54-4.9 ± NA
Clinical responders, Week 44-3.5 ± 18.873.0 ± 31.54-15.3 ± 32.759.3 ± 56.182.2 ± 7.92-1.5 ± NA-1.8 ± 7.26-3.9 ± NA
Clinical responders, Week 52-2.8 ± 18.91-2.1 ± 18.36-13.9 ± 37.0610.2 ± 55.662.7 ± 10.77-0.7 ± NA-4.2 ± 11.29-4.6 ± NA
Clinical non-responders, Week 20-1.7 ± 10.511.4 ± 2.83-4.9 ± 8.36-6.2 ± 15.3510.9 ± 15.47-0.6 ± 0.71-4.8 ± 6.69-0.5 ± 1.68
Clinical non-responders, Week 28-2.2 ± 7.71-0.6 ± 1.43-0.6 ± 6.82-5.7 ± 15.267.3 ± 12.63-0.7 ± 0.81-5.8 ± 7.736.8 ± 9.10
Clinical non-responders, Week 36-1.7 ± 8.940.4 ± 0.51-3.4 ± 8.04-6.1 ± 13.287.3 ± 12.630.6 ± 0.50-4.1 ± 7.7712.7 ± 11.20
Clinical non-responders, Week 44-1.9 ± 7.830.4 ± 0.51-2.3 ± 9.37-6.2 ± 13.157.3 ± 12.63-0.7 ± 0.95-5.8 ± 7.558.6 ± 8.55
Clinical non-responders, Week 52-1.9 ± 8.110.4 ± 0.51-2.2 ± 9.28-6.3 ± 11.717.3 ± 12.630.0 ± 0.33-5.8 ± 7.664.9 ± 10.60
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.822 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -2.0 · 95% CI -19.83 to 15.83
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.386 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -6.4 · 95% CI -20.97 to 8.25
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.136 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 12.9 · 95% CI -4.22 to 29.95
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.912 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.0 · 95% CI -17.87 to 19.97
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.118 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -12.3 · 95% CI -27.77 to 3.25
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.171 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 12.5 · 95% CI -5.61 to 30.65
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.479 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -6.9 · 95% CI -26.50 to 12.63
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.037 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -17.1 · 95% CI -33.12 to -1.04Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.463 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 6.9 · 95% CI -11.86 to 25.65
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.627 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -4.6 · 95% CI -23.59 to 14.37
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.122 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -12.2 · 95% CI -27.75 to 3.37
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.243 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 10.7 · 95% CI -7.49 to 28.89
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.658 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -4.2 · 95% CI -22.95 to 14.63
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.115 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -12.3 · 95% CI -27.69 to 3.12
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.267 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 10.0 · 95% CI -7.96 to 28.06
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.974 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.2 · 95% CI -9.74 to 10.06
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.882 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.5 · 95% CI -7.61 to 6.55
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.982 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.1 · 95% CI -7.92 to 7.75
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.673 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.2 · 95% CI -8.11 to 12.51
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.467 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.7 · 95% CI -4.64 to 10.04
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.583 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.2 · 95% CI -5.79 to 10.23
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.564 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.5 · 95% CI -13.33 to 24.31
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.728 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -2.4 · 95% CI -15.74 to 11.04
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.460 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.5 · 95% CI -9.16 to 20.08
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.253 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 12.0 · 95% CI -8.72 to 32.75
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.884 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.1 · 95% CI -13.67 to 15.84
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.474 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.8 · 95% CI -10.28 to 21.95
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.727 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 3.6 · 95% CI -17.03 to 24.30
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.780 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.1 · 95% CI -12.63 to 16.78
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.424 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 6.5 · 95% CI -9.57 to 22.54
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.841 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1.3 · 95% CI -14.23 to 11.62
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.702 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -2.1 · 95% CI -12.94 to 8.75
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.353 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.7 · 95% CI -6.43 to 17.83
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.770 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.1 · 95% CI -11.89 to 16.00
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.367 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -5.3 · 95% CI -17.04 to 6.37
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.291 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 7.0 · 95% CI -6.09 to 20.07
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.942 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.7 · 95% CI -20.87 to 19.40
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.162 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -12.0 · 95% CI -28.89 to 4.91
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.253 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 10.9 · 95% CI -7.96 to 29.82
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.617 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.5 · 95% CI -16.25 to 27.21
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.515 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -6.0 · 95% CI -24.22 to 12.24
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.180 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 13.8 · 95% CI -6.53 to 34.23
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.972 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.4 · 95% CI -21.86 to 21.09
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.589 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -4.9 · 95% CI -22.94 to 13.10
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.168 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 14.1 · 95% CI -6.07 to 34.22
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.712 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.9 · 95% CI -8.50 to 12.36
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.465 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -2.3 · 95% CI -8.41 to 3.90
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.924 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.3 · 95% CI -6.83 to 7.52
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.938 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.4 · 95% CI -8.88 to 9.60
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.410 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 2.2 · 95% CI -3.17 to 7.64
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.941 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.2 · 95% CI -5.89 to 6.35
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.872 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.7 · 95% CI -8.23 to 9.67
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.692 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1.0 · 95% CI -6.27 to 4.20
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.896 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.4 · 95% CI -6.32 to 5.54
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.826 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.0 · 95% CI -7.92 to 9.87
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.885 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.4 · 95% CI -4.82 to 5.58
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.964 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.1 · 95% CI -6.03 to 5.76
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.806 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.1 · 95% CI -7.59 to 9.72
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.871 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.4 · 95% CI -4.65 to 5.47
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.850 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.5 · 95% CI -6.28 to 5.19
SecondaryChange From Induction Baseline in IBDQ at Week 52

The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The total score ranges from 32 to 224 using the 7-point response options, with higher scores indicating better health-related quality of life. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function, and social function. Each subscale can be computed with total scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Induction Baseline in IBDQ at Week 52
units on a scaleUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders43.9 ± 38.0656.4 ± 14.5282.3 ± 35.5945.3 ± 49.89-5.0 ± NA———
Non-responders20.8 ± 43.5826.0 ± 33.1425.9 ± 47.052.9 ± 35.254.8 ± 16.4235.5 ± 28.7845.4 ± 36.1641.5 ± 24.75
Clinical responders42.8 ± 44.1346.6 ± 27.7670.7 ± 46.9926.6 ± 53.114.8 ± 18.7068.0 ± NA34.5 ± 4.9524.0 ± NA
Clinical non-responders9.4 ± 31.4613.5 ± 19.099.8 ± 30.81-1.5 ± 5.810.0 ± 0.0024.6 ± 23.1752.7 ± 49.0359.0 ± NA
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.792 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -3.9 · 95% CI -33.73 to 25.90
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.179 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 18.1 · 95% CI -8.62 to 44.75
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.230 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -19.1 · 95% CI -50.87 to 12.63
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.337 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 16.4 · 95% CI -17.54 to 50.40
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.924 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.1 · 95% CI -21.75 to 23.93
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.373 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -11.7 · 95% CI -37.69 to 14.35
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.813 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -3.1 · 95% CI -28.94 to 22.79
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.651 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.3 · 95% CI -18.02 to 28.65
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.065 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -23.8 · 95% CI -49.12 to 1.49Prespecified statistically significant at 0.1 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.802 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 5.3 · 95% CI -37.61 to 48.28
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.955 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.6 · 95% CI -20.46 to 21.63
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.395 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -10.6 · 95% CI -35.73 to 14.47
SecondaryChange From Induction Baseline in European Quality of Life (EuroQol) 5 Dimensions Questionnaire (EQ-5D) Index Score at Week 52

The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Health states are converted into a weighted health state index. These weights lie on a scale on which full health has a value of 1 and dead has a value of 0. A positive change represents an improvement in health-related quality of life.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Induction Baseline in European Quality of Life (EuroQol) 5 Dimensions Questionnaire (EQ-5D) Index Score at Week 52
units on a scaleUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders0.1350 ± 0.14730.1673 ± 0.10900.2274 ± 0.15240.0122 ± 0.12760.3260 ± NA———
Non-responders0.0208 ± 0.22310.0697 ± 0.20910.1090 ± 0.17910.0449 ± 0.10080.1288 ± 0.16740.1125 ± 0.22100.1542 ± 0.23770.1187 ± 0.1128
Clinical responders0.1435 ± 0.14610.1334 ± 0.17400.2306 ± 0.18400.0587 ± 0.12980.2198 ± 0.16150.4325 ± NA0.1758 ± 0.35590.1316 ± NA
Clinical non-responders-0.0577 ± 0.22250.0455 ± 0.06430.0330 ± 0.0677-0.0079 ± 0.02280.0000 ± 0.00000.0058 ± 0.07080.1325 ± 0.11480.1122 ± 0.1587
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.893 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.0082 · 95% CI -0.1299 to 0.1136
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.182 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0685 · 95% CI -0.0334 to 0.1705
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.036 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.1323 · 95% CI -0.2552 to -0.0093Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.316 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0768 · 95% CI -0.0749 to 0.2286
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.277 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0573 · 95% CI -0.0471 to 0.1617
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.467 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0428 · 95% CI -0.0741 to 0.1597
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.464 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.0360 · 95% CI -0.1336 to 0.0616
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.345 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0404 · 95% CI -0.0444 to 0.1252
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.071 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -0.0873 · 95% CI -0.1822 to 0.0076Prespecified statistically significant at 0.1 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.317 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.1109 · 95% CI -0.1109 to 0.3326
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.125 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0848 · 95% CI -0.0248 to 0.1945
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.390 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 0.0559 · 95% CI -0.0745 to 0.1864
SecondaryChange From Induction Baseline in EQ-5D VAS at Week 52

The EQ-5D is a standardized instrument for use as a measure of health-related quality of life. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively. A positive change represents an improvement in health-related quality of life.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Induction Baseline in EQ-5D VAS at Week 52
units on a scaleUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders12.9 ± 14.6526.9 ± 12.8034.8 ± 22.555.0 ± 17.805.0 ± NA———
Non-responders12.3 ± 24.7911.9 ± 18.7313.9 ± 27.814.7 ± 14.2212.2 ± 16.0117.5 ± 16.5820.3 ± 21.230.0 ± 15.00
Clinical responders18.2 ± 19.1922.2 ± 17.1636.1 ± 26.198.1 ± 17.9515.6 ± 15.6340.0 ± NA11.7 ± 16.07-15.0 ± NA
Clinical non-responders3.7 ± 21.795.0 ± 7.070.8 ± 11.72-1.0 ± 4.240.0 ± 0.0010.0 ± 8.6629.0 ± 25.367.5 ± 10.61
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.263 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 8.7 · 95% CI -6.79 to 24.16
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.031 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 15.2 · 95% CI 1.47 to 28.93Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.135 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -12.0 · 95% CI -27.93 to 3.90
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.458 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 6.3 · 95% CI -10.61 to 23.27
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.738 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 1.9 · 95% CI -9.59 to 13.45
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.412 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -5.4 · 95% CI -18.32 to 7.60
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.534 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 3.9 · 95% CI -8.56 to 16.36
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.052 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: 11.0 · 95% CI -0.10 to 22.01Prespecified statistically significant at 0.1 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.027 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -13.9 · 95% CI -26.15 to -1.63Prespecified statistically significant at 0.05 level.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.928 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -1.0 · 95% CI -24.02 to 21.97
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.658 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -2.5 · 95% CI -13.72 to 8.77
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · ANCOVA · p = 0.601 (P-value for test of difference between each upadacitinib higher dose and upadacitinib lower dose for mean change from induction baseline using analysis of covariance with treatment as factor and induction baseline value as covariate.) · Ls mean of difference: -3.5 · 95% CI -16.96 to 9.96
SecondaryCross Tabulation of Induction Baseline and Week 52 in Total Number of Extra-Intestinal Manifestations (EIMs) of Crohn's Disease

Presented as percentage of participants with given number of EIMs at Baseline (BL) and Week (Wk) 52. EIMs of Crohn's disease included anemia, autoimmune hepatitis, axial arthropathy, bronchiectasis, chronic obstructive pulmonary disease, episcleritis, erythema nodosum, iritis, nephrolithiasis, oral aphthous ulcers, peripheral arthropathy, primary sclerosing cholangitis, pyoderma gangrenosum, Sweet's syndrome, uveitis, and venous thromboembolism.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Cross Tabulation of Induction Baseline and Week 52 in Total Number of Extra-Intestinal Manifestations (EIMs) of Crohn's Disease
percentage of participantsDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: 12 mg BIDDouble Blind Induction Phase: 24 mg BIDDouble Blind Induction Phase: 24 mg QD
0 at BL/0 at Wk 5285.710086.476.073.385.0
0 at BL/1 at Wk 527.109.116.013.310.0
0 at BL/2 at Wk 52000000
0 at BL/3 at Wk 52000000
0 at BL/4 at Wk 52000000
0 at BL/5 at Wk 52000000
0 at BL/missing at Wk 527.104.58.013.35.0
1 at BL/0 at Wk 5242.931.640.062.550.054.5
1 at BL/1 at Wk 5250.057.960.012.533.336.4
1 at BL/2 at Wk 527.15.3025.011.19.1
1 at BL/3 at Wk 52000000
1 at BL/4 at Wk 52000000
1 at BL/5 at Wk 52000000
1 at BL/missing at Wk 5205.3005.60
2 at BL/0 at Wk 5220.050.0033.3—25.0
2 at BL/1 at Wk 52025.066.733.3—25.0
2 at BL/2 at Wk 5260.025.033.333.3—50.0
2 at BL/3 at Wk 520000—0
2 at BL/4 at Wk 520000—0
2 at BL/5 at Wk 520000—0
2 at BL/missing at Wk 5220.0000—0
3 at BL/0 at Wk 52050.00—66.7—
3 at BL/1 at Wk 5250.050.00—0—
3 at BL/2 at Wk 5200100—33.3—
3 at BL/3 at Wk 52000—0—
3 at BL/4 at Wk 5250.000—0—
3 at BL/5 at Wk 52000—0—
3 at BL/missing at Wk 52000—0—
4 at BL/0 at Wk 5201000———
4 at BL/1 at Wk 52000———
4 at BL/2 at Wk 52000———
4 at BL/3 at Wk 52000———
4 at BL/4 at Wk 5210000———
4 at BL/5 at Wk 52000———
4 at BL/missing at Wk 5200100———
5 at BL/0 at Wk 520—————
5 at BL/1 at Wk 520—————
5 at BL/2 at Wk 520—————
5 at BL/3 at Wk 520—————
5 at BL/4 at Wk 520—————
5 at BL/5 at Wk 52100—————
5 at BL/missing at Wk 520—————
SecondaryPercentage of Participants Who Achieve Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline

Remission at Week 52 is defined as endoscopic remission at Week 52 AND clinical remission at Week 52. Endoscopic remission: SES-CD ≤ 4 and at least 2-point reduction versus Baseline and no subscore \> 1 in any individual variable. Clinical remission: average daily stool frequency ≤ 1.5 and not worse than Baseline AND average daily abdominal pain ≤ 1.0 and not worse than Baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe). Details of the SES-CD scale are provided in the description of the first primary endpoint.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders50.0—0—————
Non-responders0000000—
Clinical responders25.0000000—
Clinical non-responders0000—00—
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -50.0 · 95% CI -99.0 to -1.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -25.0 · 95% CI -55.0 to 5.0Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
SecondaryPercentage of Participants Who Achieve Modified Clinical Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline And Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline

Modified clinical remission was defined as average daily stool frequency \<= 2.8 and not worse than induction baseline AND average daily abdominal pain \<= 1.0 and not worse than induction baseline. The very soft/liquid stool frequency and abdominal pain scores at a visit were the average of the daily values reported during the 7 usable days preceding the scheduled assessment visit. Abdominal Pain was rated on a 4-point scale from 0 (none) to 3 (severe).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Modified Clinical Remission at Week 52 Among Participants With Isolated Ileal Crohn's Disease at Baseline And Daily Stool Frequency ≥ 4.0 or Daily Abdominal Pain ≥ 2.0 at Induction Baseline
percentage of participantsUpadacitinib 3 mg BID in Extension/Upadacitinib in InductionUpadacitinib 6 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 12 mg BID in Extension/ Upadacitinib in InductionUpadacitinib 24 mg QD in Extension/ Upadacitinib in InductionUpadacitinib 3 mg BID in Extension/ Placebo in InductionUpadacitinib 6 mg BID in Extension/ Placebo in InductionUpadacitinib 12 mg BID in Extension/ Placebo in InductionUpadacitinib 24 mg QD in Extension/ Placebo in Induction
Responders66.7—0—————
Non-responders033.30050.000—
Clinical responders33.350.00050.000—
Clinical non-responders0000—00—
Statistical analysis
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -66.7 · 95% CI -100.0 to -13.3Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.250 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 33.3 · 95% CI -20.0 to 86.7Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 6 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): 16.7 · 95% CI -62.2 to 95.6Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 12 mg BID in Extension/ Upadacitinib in Induction · Chi-squared · p = 0.500 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -71.1 to 4.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.
  • Upadacitinib 3 mg BID in Extension/Upadacitinib in Induction vs Upadacitinib 24 mg QD in Extension/ Upadacitinib in Induction · Chi-squared · p = 1.000 (P-value was calculated based on chi-square test (or Fisher's exact test if \>= 20% of the cells had expected cell count \< 5).) · Risk difference (rd): -33.3 · 95% CI -71.1 to 4.4Risk difference = (upadacitinib higher dose - upadacitinib 3 mg BID). 95% confidence intervals for risk difference were calculated based on normal approximation using proc FREQ.

Adverse events

Collected over Treatment-emergent adverse events AEs (TEAEs): collected from the first dose of study drug through Week 52 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Induction Phase: Placebo BID0/37 (0%)2/37 (5.4%)25/37 (67.6%)
Double-Blind Induction Phase: Upadacitinib 3 mg BID0/39 (0%)5/39 (12.8%)32/39 (82.1%)
Double-Blind Induction Phase: Upadacitinib 6 mg BID0/37 (0%)2/37 (5.4%)27/37 (73%)
Double Blind Induction Phase: 12 mg BID0/36 (0%)10/36 (27.8%)23/36 (63.9%)
Double Blind Induction Phase: 24 mg BID0/36 (0%)3/36 (8.3%)28/36 (77.8%)
Double Blind Induction Phase: 24 mg QD0/35 (0%)7/35 (20%)25/35 (71.4%)
Double Blind Extension Phase: 3 mg BID0/60 (0%)18/60 (30%)31/60 (51.7%)
Double Blind Extension Phase: 6 mg BID0/23 (0%)2/23 (8.7%)9/23 (39.1%)
Double Blind Extension 12 mg BID0/59 (0%)5/59 (8.5%)35/59 (59.3%)
Double Blind Extension 24 mg QD0/36 (0%)5/36 (13.9%)14/36 (38.9%)
Open Label Extension Subjects Never Received OL 24 mg BID0/33 (0%)11/33 (33.3%)8/33 (24.2%)
Open Label Extension Subjects Received OL 24 mg BID0/27 (0%)4/27 (14.8%)17/27 (63%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: 12 mg BIDDouble Blind Induction Phase: 24 mg BIDDouble Blind Induction Phase: 24 mg QDDouble Blind Extension Phase: 3 mg BIDDouble Blind Extension Phase: 6 mg BIDDouble Blind Extension 12 mg BIDDouble Blind Extension 24 mg QDOpen Label Extension Subjects Never Received OL 24 mg BIDOpen Label Extension Subjects Received OL 24 mg BID
CROHN'S DISEASEGastrointestinal disorders1/372/392/371/362/360/357/600/232/594/367/333/27
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/370/390/371/360/362/352/600/231/590/361/330/27
ABDOMINAL PAINGastrointestinal disorders0/370/390/370/360/360/350/600/231/592/361/330/27
CHEST PAINGeneral disorders0/370/390/370/360/360/350/601/230/590/360/330/27
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/370/390/370/360/360/351/601/230/590/360/330/27
ABDOMINAL ABSCESSInfections and infestations0/370/390/370/360/360/351/600/231/590/360/331/27
NEPHROLITHIASISRenal and urinary disorders0/370/390/371/360/360/350/600/230/590/360/331/27
SINUS BRADYCARDIACardiac disorders0/370/390/370/360/360/350/600/230/590/361/330/27
FISTULA OF SMALL INTESTINEGastrointestinal disorders0/370/390/370/360/360/350/600/230/590/361/330/27
INTESTINAL STENOSISGastrointestinal disorders0/370/390/370/360/360/351/600/230/590/361/330/27
Most frequent other events
Showing 10 of 58
Most frequent other events
EventDouble-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: 12 mg BIDDouble Blind Induction Phase: 24 mg BIDDouble Blind Induction Phase: 24 mg QDDouble Blind Extension Phase: 3 mg BIDDouble Blind Extension Phase: 6 mg BIDDouble Blind Extension 12 mg BIDDouble Blind Extension 24 mg QDOpen Label Extension Subjects Never Received OL 24 mg BIDOpen Label Extension Subjects Received OL 24 mg BID
HEADACHENervous system disorders3/377/397/373/368/365/350/601/235/591/360/330/27
FATIGUEGeneral disorders3/378/392/372/364/362/352/601/232/592/360/330/27
CROHN'S DISEASEGastrointestinal disorders6/376/394/377/363/362/356/602/236/592/362/333/27
ABDOMINAL PAINGastrointestinal disorders0/375/392/376/362/365/354/600/231/590/360/330/27
URINARY TRACT INFECTIONInfections and infestations2/371/394/370/365/362/354/601/235/590/360/330/27
PYREXIAGeneral disorders3/375/390/372/361/361/351/600/233/591/360/330/27
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/374/394/374/363/362/355/601/237/592/362/333/27
VOMITINGGastrointestinal disorders1/374/391/373/363/361/351/600/233/591/361/333/27
BRONCHITISInfections and infestations0/370/390/370/360/360/350/600/230/590/360/333/27
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/372/392/374/364/361/353/601/234/592/360/332/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDTotal
Mean40.5 ± 12.1439.7 ± 14.0340.5 ± 13.4140.8 ± 15.1842.5 ± 10.0240.2 ± 12.6040.7 ± 12.90
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDTotal
Female241921172519125
Male13201619111695
High-sensitivity C-reactive protein (hsCRP)
High-sensitivity C-reactive protein (hsCRP)(mg/L)Double-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDTotal
Mean20.8 ± 34.2923.6 ± 51.4317.9 ± 17.9226.9 ± 28.8617.1 ± 26.4917.1 ± 20.8320.6 ± 32.11
Fecal Calprotectin
Fecal Calprotectin(mcg/g)Double-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDTotal
Mean1734.7 ± 2444.071925.9 ± 2804.072128.5 ± 1978.732067.9 ± 2250.972074.8 ± 2324.151808.7 ± 2548.111960.8 ± 2371.86
Inflammatory Bowel Disease Questionnaire (IBDQ)
Inflammatory Bowel Disease Questionnaire (IBDQ)(units on a scale)Double-Blind Induction Phase: Placebo BIDDouble-Blind Induction Phase: Upadacitinib 3 mg BIDDouble-Blind Induction Phase: Upadacitinib 6 mg BIDDouble Blind Induction Phase: Upadacitinib 12 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg BIDDouble Blind Induction Phase: Upadacitinib 24 mg QDTotal
Mean118.0 ± 28.45115.2 ± 27.48113.7 ± 25.86115.2 ± 36.05113.8 ± 35.97120.7 ± 36.25116.1 ± 31.60
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14;16(3):444-451. doi: 10.1093/ecco-jcc/jjab161. PubMed 34546360 ↗
  • Aguilar D, Revilla L, Garrido-Trigo A, Panes J, Lozano JJ, Planell N, Esteller M, Lacerda AP, Guay H, Butler J, Davis JW, Salas A. Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study. Inflamm Bowel Dis. 2021 Nov 15;27(12):1999-2009. doi: 10.1093/ibd/izab116. PubMed 34042156 ↗
  • Peyrin-Biroulet L, Louis E, Loftus EV Jr, Lacerda A, Zhou Q, Sanchez Gonzalez Y, Ghosh S. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. Adv Ther. 2021 May;38(5):2339-2352. doi: 10.1007/s12325-021-01660-7. Epub 2021 Mar 23. PubMed 33755884 ↗
  • Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020 Jun;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Epub 2020 Feb 8. PubMed 32044319 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Nov 2016, 20 months.

Results were first posted in Aug 2023, 6 years 8 months after primary completion. A results delay was requested in Nov 2017.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2015
First posted
Feb 19, 2015
StartActual
Mar 17, 2015
Primary completionActual
Nov 25, 2016
CompletionActual
Aug 3, 2017
Results delay requested
Nov 1, 2017
Results first posted
Aug 14, 2023
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02365649
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2015
Start date
Mar 17, 2015
Primary completion
Nov 25, 2016
Completion
Aug 3, 2017
Results posted
Aug 14, 2023
Last update
Dec 27, 2023

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion